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Abstract
Adaptive designs are increasingly adopted to make the process of drug develop-
ment more efficient. In particular, seamless phase II/III clinical trials allow interim
adaptations such as early stopping for futility or selection of the most promising
treatment. Furthermore, targeted therapy trials include an interim analysis to se-
lect a subgroup with the largest observed treatment effect. However, despite their
efficiency, data dependent adaptations lead to multiplicity and selection issues. This
is because data are used for both treatment or subgroup selection as well as for the
confirmatory analysis of treatment efficacy. Specifically, selection rules applied at
the interim stage lead to overoptimistic and thus biased effect estimates. In this
thesis, we investigate the bias that arises due to selection and develop unbiased es-
timators that correct for treatment or subgroup selection in two-stage confirmatory
clinical trials with time-to-event data.
When analysis is based on time-to-event data, censoring at the interim analysis vi-
olates the assumption of independence between stage 1 and stage 2 data, which is a
crucial assumption of existing methods for normally distributed data. The indepen-
dent increments structure of stagewise log-rank test statistics has been beneficial for
hypothesis testing in this setting, where group sequential methods have been utilised
based on the log-rank test statistic for time-to-event data. We therefore incorpo-
rate the independent increments structure to derive unbiased estimators based on
asymptotic normality of the log-rank test statistic. Additionally, when considering
treatment selection, we address the issue of correlation between stage 1 estimates
due to the common control arm for time-to-event outcomes.
We give the joint distribution of stagewise log hazard ratios and using the technique
of Rao-Blackwellisation, we derive asymptotically uniformly minimum variance un-
biased estimators conditional on selection rules for time-to-event outcomes. We ex-
amine the bias and mean squared error of conventional estimates and compare these,
by simulation, to our unbiased and efficient estimators, which correct for treatment
or subgroup selection and correlation due to both censoring and the common control
arm. We show that, due to the asymptotic normality assumptions, our estimators




The focus of this thesis is point estimation of treatment effects correcting for se-
lection bias in two-stage confirmatory clinical trials with time-to-event data. Two
forms of selection bias are explored. First, bias due to treatment selection in multi-
arm seamless phase II/III clinical trials is assessed for both normally distributed
outcomes and time-to-event outcomes, with the aim to develop new unbiased es-
timators for time-to-event outcomes. Second, bias due to subpopulation selection
is investigated in the setting of two-stage targeted therapy trials, with the aim to
develop new unbiased estimators.
In recent years, adaptive clinical trial designs have been adopted for use in drug
development due to their ability to incorporate interim adaptations and test multiple
hypotheses in a single trial [Hatfield et al., 2016]. In particular, seamless phase
II/III clinical trials, which combine the goals of a phase II clinical trial with those
of a phase III clinical trial, aim to accelerate the process of drug development by
eliminating the time delay between conventionally separate phase II and III trials
[Korn and Freidlin, 2017]. Much of the focus of statistical methodology for adaptive
designs, specifically for seamless phase II/III clinical trials, has been on multiple
1
hypothesis testing [Bretz et al., 2006, Stallard and Todd, 2003]. Point estimation,
on the other hand, specifically for two-stage trials with time-to-event data, seems to
have attracted little attention. The overall aim of this thesis is therefore to explore
the issues with time-to-event data analysis in this setting and develop unbiased
estimators that correct for bias due to treatment or subpopulation selection.
In seamless phase II/III clinical trials, stage 1 involves investigation of multiple
experimental treatments with the aim to select the most efficacious treatment at
the interim analysis for further investigation in the second stage. This selection
leads to biased estimation at the final analysis, since stage 1 data are used for both
treatment selection and for the confirmatory analysis [Bauer and Posch, 2004]. In
addition, correlation between stage 1 estimates arises as all experimental treatments
are compared to a common control arm. In targeted therapy trials, selection with
respect to a subgroup is made at the interim analysis based on the treatment effect
observed in the subpopulation and the full population. As with treatment selection,
this selection of the most promising population leads to biased estimation at the final
analysis [Kimani et al., 2015]. Therefore, new unbiased estimators are warranted
that utilise all trial data while considering both the selection rules and the correlation
between estimates.
For normally distributed outcomes in seamless phase II/III clinical trials, unbi-
ased estimators accounting for treatment selection exist for various trial scenarios.
These include, early stopping for futility or efficacy [Kimani et al., 2013], and es-
timating treatment efficacy for not only the selected treatment but more than one
experimental treatment [Bowden and Glimm, 2008]. These estimators utilise the
technique of Rao-Blackwellisation, which involves conditioning on the selection rule
and complete, sufficient statistics in order to derive a uniformly minimum variance
conditionally unbiased estimator (UMVCUE). However, for time-to-event outcomes,
such methods of efficient and unbiased estimation have not been investigated with
2
respect to selection bias. In targeted therapy trials, methods that address issues
for hypothesis testing of time-to-event outcomes have been proposed [Glimm and
Di Scala, 2015]. However, as with treatment selection, the problem of unbiased
estimation accounting for subpopulation selection with time-to-event outcomes has
been given less thought than that of hypothesis testing.
Time-to-event outcomes present additional challenges in estimation compared to
normally distributed data due to the inherent nature of censoring. The main as-
sumption of the estimators for normally distributed outcomes is that data from
stage 1 and 2 are independent. With time-to-event outcomes, this assumption is
violated, since at the interim analysis, the event of interest may not be observed
for all patients recruited in stage 1. These patients are then followed-up further in
stage 2, which therefore leads to correlated stage 1 and 2 data.
The estimators that will be developed in this thesis consider the issues that arise
in the analysis of time-to-event data in two-stage clinical trials. Specifically, the
issues that will be accounted for are the correlation between stagewise estimates
and the bias, either due to treatment selection or subpopulation selection. Fur-
thermore, derivation of point estimators will utilise the statistical technique of Rao-
Blackwellisation in order to obtain asymptotically uniformly minimum variance con-
ditionally unbiased estimators.
1.1 Outline of the thesis
An introduction to clinical trials is provided in Chapter 2 with an overview of trial
designs for each phase of drug development. The setting of clinical trials for which
the methods reported in Chapters 5 and 6 are based upon is then described.
Chapter 3 provides the statistical background for this thesis where standard sta-
tistical methods are given with a focus on point estimation. Further methods are
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presented in Chapter 4 for the analysis of time-to-event data in the conventional
setting of a single-stage two-arm clinical trial. Additionally, this chapter introduces
the asymptotic normality assumptions for survival outcome parameters.
Chapter 5 presents existing methods of treatment effect estimation in seamless phase
II/III clinical trials for normally distributed data. Bias that arises in maximum
likelihood estimation due to treatment selection is examined analytically for various
trial scenarios. An overview of current methods for unbiased estimation of normally
distributed outcomes is provided before presenting a uniformly minimum variance
conditionally unbiased estimator; this is then compared for efficiency to the biased
maximum likelihood estimator via simulations.
Methods described in Chapter 5 are then extended in Chapter 6 to account for
issues that arise in estimation of treatment effects in seamless phase II/III clinical
trials with time-to-event outcomes. Selection bias from ‘naive’ estimation, which
disregards selection and censoring, is assessed through simulations for various trial
scenarios. Current methods that address multiplicity issues in time-to-event group
sequential trials are presented with a view to using these methods to develop point
estimators for time-to-event outcomes. Two new asymptotically UMVCUEs are then
developed based on the log-rank test statistic. The first corrects for selection bias
and correlation between stagewise estimates for the setting where separate control
arms are assumed for each experimental treatment arm. The second new estimator
derived replaces this assumption to correct for selection bias and correlation due to
a common control arm. Results from a simulation study are then presented that
compare the new unbiased estimator with a common control arm to the ‘naive’
estimator.
Chapter 7 addresses issues with treatment effect estimation in targeted therapy trials
conditional on subpopulation selection. At the interim analysis, selection is made
with respect to the biomarker-positive subpopulation or the full population. For
4
each case of selection, naive estimators are presented before deriving asymptotically
unbiased estimators, conditional on selection. The estimators developed are then
compared by simulation for a range of treatment effect sizes. All simulation results
presented throughout this thesis have been programmed in the statistical language
R [R Core Team, 2017].
This thesis concludes with chapter 8, which provides a summary of the work reported




Clinical trials are prospective experimental studies conducted to assess the safety
and efficacy of a healthcare intervention in human beings. An intervention may be a
new medical treatment, a surgical procedure or a combination of existing treatments
that are thought to interact. As this thesis is concerned with time-to-event outcomes,
which are predominantly used in oncology trials, the interventions considered in this
chapter are anti-tumour cytotoxic agents.
Traditional drug development consists of a sequence of independent phases of clin-
ical trials, referred to as phase I−IV. In general, phase I and II clinical trials are
considered the learning phase of drug development, whereas phase III and IV clini-
cal trials make up the confirming phase [Sheiner, 1997]. Learning and confirmatory
trials have different goals to progress drug development with individually tailored
trial designs and methods of analysis. Phase IV clinical trials are post-licensing
surveillance studies which are primarily interested in the long-term implementation
of a drug. This thesis is interested in treatment effect estimation for pre-licensed
drugs and therefore phase IV clinical trials are not discussed further in this the-
sis. The following sections give an overview of clinical trial designs for each phase
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of development to provide the context of clinical trials that is the focus in this
thesis.
2.1 Phase I clinical trials
The primary objective of phase I trials is to assess the safety profile of a drug whilst
determining the biological optimal dose [Piantadosi, 2005]. These trials are known
as ‘first-in-man’ studies as they are conventionally the first time a new treatment
is introduced in humans for clinical assessment. They may also be the first time
a combination of two or more existing treatments is explored for the joint safety
profile and dosing regimen.
Phase I oncology trials are small sample studies generally conducted with patients
who have tried and failed existing cancer therapies. For cytotoxic agents, it is be-
lieved that the dose-toxicity and dose-response relationship for outcomes of toxicity
and efficacy are monotonically increasing. Therefore, the primary outcome measure
of a phase I trial is the Maximum Tolerated Dose (MTD). This is considered the
most effective tolerable dose and is estimated by observing the number of Dose Lim-
iting Toxicities (DLTs) at different dose levels. Phase I studies follow a sequential
dose-escalation design and can be either rule-based or model-based designs [George
et al., 2016].
Traditionally in phase I oncology trials, rule-based designs such as the 3+3 and
variations of this design were commonly used due to their simplicity and familiarity
with clinical investigators. A prespecified set of dose levels is defined and allocation
of 3 patients starts at the lowest dose level, with consecutive escalation of doses
continued until the MTD is achieved. In this design, the MTD is defined as the
highest dose level at which no more than 33% toxicities are observed [George et al.,
2016]. If no DLTs occur at the current dose level, the dose is escalated and a new
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cohort of 3 patients are recruited. If one or more toxicities occur at a given dose,
then the dose is de-escalated for the subsequent cohort. This process is repeated
until the MTD is found or all dose levels have been investigated. The escalation/de-
escalation decision is only based on data from the current cohort of 3 patients at
a given dose level. Hence, although commonly used, such rule-based designs are
inefficient due to slow dose escalation and inefficient use of all trial data.
Alternatives to rule-based designs are model-based designs which explicitly fit para-
metric models for the dose-toxicity relationship. The most well-known model-based
design is the Continual Reassessment Method (CRM) [O’Quigley et al., 1990]. This
is a Bayesian adaptive design which is considerably more efficient both in terms of
time and estimation of the MTD compared to all rule-based designs [Machin et al.,
2004]. The most attractive feature of this design is that all accrued data are used
in the escalation/de-escalation decision to determine the next dose level, as opposed
to only the current cohort of three patients used in rule-based designs.
For the CRM, a target probability of toxicity is prespecified which may be higher
or lower than the 33% in rule-based designs. The dose-toxicity curve is modelled
after every patient is recruited and includes all accrued data to determine the next
dose level from a set of dose levels. The next dose is estimated as the one whose
probability of toxicity is closest to the target toxicity probability. Therefore, in
comparison to rule based designs, this allows dose levels to be skipped in order to
reach the MTD more quickly. The MTD is determined after a fixed number of
patients have been treated. The model may take different forms, including: a power
model, a hyperbolic tangent model or a logistic model. The main assumption of
the model is that the dose-response relationship must be monotonically increasing,
which is satisfied for cytotoxic agents. The CRM was initially adopted as a Bayesian
model where prior probabilities of toxicities are elicited from clinical investigators
to determine the starting dose level. For more details on model specification see
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Conaway and Wages [2016].
Despite being attractive features of CRM, skipping of dose levels and updating
the model after only one patient may not be desirable for safety and efficiency
concerns [Green et al., 2002]. Modifications of the CRM have thus been proposed
that address these concerns. To avoid time delays after each patient, the model may
only be updated after a set number of patients have been observed for DLTs; for
familiarity with rule-based designs, this may be set to 3 patients. Additionally, to
avoid skipping to higher doses too quickly, the model may incorporate a restriction
of skipping three or more dose levels, for example.
2.2 Phase II clinical trials
The second stage of drug development, defined as phase II, aims to determine an ini-
tial proof of activity of an experimental treatment. Phase II trials can be categorised
into early phase II and late phase II trials depending on the stage of development.
Early phase II oncology trials are usually single-arm non-randomised studies with
small sample sizes [Machin et al., 2009], where the MTD found in phase I is brought
forward into phase II to establish treatment activity whilst also monitoring toxicity.
Late Phase II trials are randomised trials which aim to assess the activity of mul-
tiple experimental treatments simultaneously in order to select the most promising
treatment to investigate further in phase III. As phase II trials are generally the first
assessment of treatment efficacy, the primary outcome measure is usually a short
objective measure and may be surrogate for the primary outcome in the subsequent
phase III trial. For example, in phase II oncology trials, tumour response is typically
considered a surrogate for overall survival time in a phase III trial.
Designs of phase II trials reflect the stage of development and depend on several fac-
tors including the primary outcome measure, the number of experimental treatments
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and the number of stages. Early phase II designs are either single-arm single-stage
designs [A’Hern, 2001, Fleming, 1982, Jung and Kim, 2004] or single-arm two-stage
designs [Simon, 1989]. The two-stage designs incorporate an interim analysis to
allow early stopping for inadequate activity. There are two variants of Simon’s two-
stage design; namely the minimax and optimal design. The minimax design aims
to minimise the overall number of patients in the trial, whereas the optimal design
aims to reduce the number of patients treated, should the treatment be found to be
ineffective in stage 1. The optimal design is therefore favourable if the treatment
is ineffective as it has a higher probability of stopping accrual in the second stage.
On the other hand, if the treatment is found to be effective in stage 1, then the
overall sample size would be larger than the minimax design. These designs follow
a frequentist approach where critical values for desirable and undesirable levels of
tumour response are defined for standard hypothesis testing. More details on these
designs can found in Jung [2016].
Late phase II trial designs may be used to compare one or more experimental
treatments or treatment doses, with the aim of selecting the most promising treat-
ment/dose or dropping the least effective. Many randomised phase II designs have
been proposed such as the ‘pick a winner’ design proposed by Simon et al. [1985].
Sargent and Goldberg [2001] proposed a more flexible design similar to Simon et al.
that considers secondary endpoints when the observed treatment differences are
small. Jung [2008] proposed an extension to Simon’s [1989] two-stage single-arm
design for randomised phase II trials with a control arm and one experimental arm.
They provide a single-stage variation as well as the two-stage minimax and opti-
mal designs. Rubinstein et al. [2005] provide a review for different phase II trial
designs.
All the above designs assume a single primary outcome of activity which is usually
the case in phase II trials. However, safety endpoints such as treatment tolerabil-
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ity and toxicity are also monitored as secondary endpoints. The Bryant and Day
[1995] design incorporates both safety and activity through a dual primary outcome
measure of response and toxicity in a two-stage design. However, this design is only
practically appropriate if response and toxicity assessments can be made in a similar
time frame to determine the primary outcome of each patient, in order not to delay
accrual in the second stage.
2.3 Phase III clinical trials
The final stage of drug development, before a treatment is considered for licensing,
involves a large randomised, usually multi-centre, phase III clinical trial. Phase III
clinical trials aim to provide a definitive assessment of treatment efficacy compared
to a control treatment and are thus referred to as confirmatory clinical trials. The
control treatment is generally the current standard of care for the disease in question.
If no standard treatment exists then a placebo is generally used in order to provide
a comparator arm for the experimental treatment.
Patients are randomly allocated to either the experimental treatment or control
treatment, with allocation typically blinded to the patient and clinician. This is
known as a double-blind trial and ensures allocation bias is minimised. Phase III
clinical trials can take various designs depending on the aim of the treatment-control
comparison and primary outcome measure. For example, sample size calculations
vary for superiority aims, compared to equivalence or inferiority of treatment versus
control [Green et al., 2002]. However, most commonly used sample size calculations
are based on classical hypothesis testing with type II error rates minimised with a
large sample size and confirmatory aims [Machin et al., 2009].
Trials with time-to-event outcomes are event-driven, which means statistical power
and sample size calculations depend on the number of events as opposed to the
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number of patients. Lakatos [2016] gives an overview of sample size calculations
for survival trials in the context of oncology. Efficacy of treatments with survival
outcomes are estimated in terms of a hazard ratio. This is a ratio of the death rates
on the treatment and control arms. An overview of methods for time-to-event data
analysis is provided in Chapter 4.
2.4 Adaptive seamless designs
As the combined goal of each phase of drug development is to determine whether
an experimental treatment is safe and efficacious for use in patient care, in order
to reduce the time delay between each study set up, it would be beneficial to com-
bine these phases of clinical trials where appropriate. Adaptive seamless designs
aim to eliminate the time delay between trials, whilst making more efficient use
of patient data by incorporating objectives of multiple phases into a single, opera-
tionally and/or inferentially seamless trial. Operationally seamless trials make use
of one trial protocol for the multiple stages, but data from each stage are analysed
separately, while for inferentially seamless trials, analysis at the end of each stage
includes all accrued data from previous stages.
The main feature of an adaptive design is the use of interim analyses. This allows
design modifications to be made after each interim analysis. These modifications
may include early stopping for futility or efficacy, sample size adjustments [Chuang-
Stein et al., 2006] and selection of treatment arms [Posch et al., 2005]. Each interim
analysis is conducted at the end of a stage in the trial, which therefore results in a
multi-stage design. This multi-stage approach makes more efficient use of patient
data, as the same data may be used to answer two or more clinical questions leading
to reduced sample sizes compared to conducting separate trials.
However, incorporating such adaptations compromises the overall type I error rate
12
due to multiplicity issues. The main sources of multiplicity in confirmatory trials are
repeated hypothesis testing at multiple interim analyses and investigating multiple
experimental treatments for comparison with a common control group. Methods
exist to control the type I error rate for these conditions known as ‘multiple com-
parison procedures’ and ‘group sequential procedures’ [Bretz et al., 2006, Jennison
and Turnbull, 2000]. However, these methods require decision rules to be speci-
fied in advance. This is known as a ‘prespecified adaptivity design’ [Bretz et al.,
2009] and is the setting considered in this thesis. For more details on multiplicity
issues and multiple comparison procedures for multi-stage clinical trials see Xi et al.
[2016].
Adaptive seamless designs that combine a late phase II trial and a phase III trial
into one seamless trial with two stages, where stage 1 and 2 represent phase II and
III components of a trial, are commonly referred to as seamless phase II/III clinical
trials [Bretz et al., 2006]. Despite the attractive features of adaptive designs dis-
cussed above, the prespecified adaptivity requirement may eliminate the flexibility
of modifying the phase III trial design, which may be desired based on results of
the phase II trial. Furthermore, in addition to adjusting statistical tests to account
for design modifications, adaptive trials require a greater time commitment both at
the design and planning stage as well as from sponsoring organisations in contrast
to an individual phase II trial that may not lead to a phase III trial [Korn and
Freidlin, 2017]. Therefore, despite the many advantages of adaptive designs, the
costs associated with such designs also need to be considered in practice.
2.4.1 Seamless phase II/III clinical trials
Seamless phase II/III clinical trials combine the aims of a late phase II and phase
III trial into one operationally and inferentially seamless clinical trial [Korn et al.,
2012]. The design of such a trial forms a two-stage multi-arm setting, where stage
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s ∈ {1, ...,K}
Figure 2.1: Seamless phase II/III clinical trial schema
1 addresses phase II objectives, investigating the activity of multiple treatments
simultaneously, and stage 2 addresses the phase III objective regarding treatment
efficacy. Figure 2.1 depicts this two-stage multi-arm setting.
In Chapters 5 and 6, like Stallard and Todd [2003], the phase II objective is defined
as selection of the most promising treatment among several experimental treatments.
In stage 1, patients are randomised to multiple experimental treatment arms plus a
common control arm. At the end of stage 1, an interim analysis is performed where
the ‘best’ performing experimental treatment is selected, according to a prespecified
selection criterion, for further investigation in the stage 2 confirmatory phase III
setting. Accrual continues in stage 2 where additional patients are randomised to
the selected treatment and control arms. A final analysis is then conducted which
utilises data accrued in both stages 1 and 2. This inferentially seamless two-stage
approach is therefore said to be efficient in terms of data analysis as phase II data
are not only used for the phase II objective but also for the phase III objective.
In addition to treatment selection, further design modifications may be incorporated
at the interim analysis. These include early stopping for futility or efficacy [Stallard
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and Todd, 2003] or adjusting the sample size for the subsequent stage [Bretz et al.,
2006]. For example, if a treatment indicates inadequate efficacy at the interim
analysis, the trial may stop early for futility. On the other hand, if the data show
clear evidence of a beneficial effect, further patients may not be required. Hence,
combining both phase II and phase III trial aims into one seamless phase II/III trial
makes drug development efficient, as it is not only time- and cost-effective, but also
answers multiple clinical questions with potentially smaller sample sizes.
Therefore, seamless phase II/III trials are attractive for use in multi-arm clinical
trials. However, due to the interim analysis, challenges arise in statistical inference.
Estimation following treatment selection is biased due to multiple use of stage 1
data. Existing methods for unbiased estimation for normally distributed outcomes
that correct for such selection bias are presented in Chapter 5. However, these
methods cannot be used in the analysis of time-to-event data as such data are not
normally distributed and include censored event times. Therefore, Chapters 6 and 7
develop methods for treatment effect estimation that correct for selection bias which




There are three main areas of statistical inference known as point estimation, confi-
dence interval estimation and hypothesis testing. This thesis is concerned with point
estimation in confirmatory clinical trials, and therefore this chapter introduces sta-
tistical inference tools that are used throughout this thesis, particularly focussing
on point estimation. The methods described in this chapter can be found in theo-
retical statistics textbooks such as Lindgren [1993], Roussas [2007] and Young and
Smith [2005]. This chapter begins by introducing probability distributions consid-
ered in this thesis, followed by properties of the normal distribution relevant to later
chapters, and ends with statistical properties of point estimators.
3.1 Probability density function
Suppose X is a random variable which has probability distribution that depends
on an unknown parameter θ. Let x denote the observed value of X, then the
probability distribution of X is specified by a probability density function (pdf) if X
is continuous or a probability mass function (pmf) if X is discrete. This is denoted
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by fθ(x), where the index indicates the dependence on θ. The probability that X
is less than or equal to x is described by the cumulative distribution function (cdf),
Fθ(x).
In parametric inference, fθ(x) is of a known analytic form, whereas non-parametric
inference does not assume the data follow a known statistical distribution. Chapter
4 alludes to semi-parametric inference but otherwise we are only concerned with
parametric inference in this thesis.
3.1.1 Multivariate distribution
A function f(x1, ..., xn) from Rn to R is called a joint pdf of the continuous random
vector (X1, ..., Xn) if, for any subset A ⊂ Rn,





f(x1, ..., xn)dx1 . . . dxn.
The joint cdf of X1, ..., Xn is thus






f(u1, ..., un)du1 . . . dun ∀(x1, ..., xn) ∈ Rn.
Transformation of random variables
Transformation of random variables is an important technique that allows the dis-
tribution of a desired random vector to be found from a known distribution of a
related random vector. This tool will be used in later chapters and is thus described
in general below. Assuming the relation is a one-to-one multivariate transformation,
the density of the transformed joint distribution is found as follows.
Let X1, ..., Xn be random variables with joint pdf f(x1, ..., xn). Let g(y1, ..., yn)
be the joint pdf of Y1, ...Yn, where Yi = hi(X1, ..., Xn) for i = 1, ..., n and hi are
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invertible functions. Suppose the equations yi can be solved for xi = h
−1
i (y1, ..., yn)
and the inverse functions h−1i are differentiable. Then the joint pdf of Y1, ..., Yn
is
f(y1, ..., yn) = f(h
−1
1 (y1, ..., yn), ..., h
−1
n (y1, ..., yn))|J |, (3.1)



















This section gives general properties of statistical distributions considered in this
thesis. Probability density functions, f(x), are given for continuous distributions
while probability mass functions, P (X = x), are given for discrete distributions,
with their respective expected value, E(X), and variance, var(X).
The hypergeometric distribution: Hyp(N, r, n)




















If N →∞, then var(X) converges to np(1− p).
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2/2σ2 , x, µ ∈ R, σ2 > 0. (3.3)
E(X) = µ;
var(X) = σ2.
The normal distribution, also called the Gaussian distribution, has many useful
properties as described in the next section.




x(µ/2)−1e−x/2, x ≥ 0, µ ∈ N>0 (3.4)
E(X) = µ;
var(X) = 2µ.






















The Weibull distribution: Weibull(µ, σ)
f(x) = µσxσ−1e−µx
σ















This is the common parametrisation used in medical research. If µ = 1 then this
reduces to the exponential distribution.
Exponential families
Some of the distribution functions given above are special cases of exponential fam-
ilies. Suppose a random vector of n independent observations, X = (X1, ..., Xn),
depends on the parameter θ = (θ1, ..., θp). Then a family of pdfs or pmfs of X is










An example of this is given for the normal distribution in Section 3.3.3.
3.3 Useful properties of the normal distribution
The normal distribution has a focal role in probability and statistics for three main
reasons [Casella and Berger, 2002]. Firstly, the distribution is analytically tractable
which means exact analytical solutions can be found easily. Secondly, the distribu-
tion has a symmetric bell-shaped density, which makes it a highly applicable choice
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for population models. The third, and perhaps most important reason, is its use
as an approximation to other distributions for large samples via the Central Limit
Theorem [Lindgren, 1993].
3.3.1 Standard normal
If a random variable X has a normal distribution with mean µ and variance σ2 then
it is common to write X ∼ N(µ, σ2), with density f(x) given in equation (3.3). If




is said to be standard normal. This is commonly written as Z ∼ N(0, 1). The








−u2/2du, respectively. Thus, the density and cumulative dis-
tribution function of any normally distributed random variable X with mean µ
and variance σ2 can be expressed in terms of the standard normal distribution by
f(x) = 1σφ(
x−µ
σ ) and F (x) = Φ(
x−µ
σ ). Figure 3.1 shows the bell shape of the normal
density function with symmetry around its mean. This implies φ(x) = φ(−x) and
Φ(−x) = 1− Φ(x).
Figure 3.1: Normal density for µ of 0 (solid), -1 (dashed) and 1 (dotted) with σ = 1.
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3.3.2 Truncated normal
The range of a normal random variable may be restricted above or below which leads
to a truncated normal distribution. The expectation of a truncated normal pdf is of









































































as shown in Appendix A.
3.3.3 Normal distribution as an example of an exponential family
distribution
It can be shown that the density function of the normal distribution with unknown
mean and variance belongs to a two parameter exponential family. Recall the density







2) = − 1
2σ2




and t2(x) = x, then





















Hence, from this parameterisation and Definition 3.4.8, the complete, sufficient











Let X̄ and S2 denote the normal sample mean and standard deviation. Then the
one-to-one transformation of T (X) to T1(X) = (X̄, S
2), implies T1(X) is complete
and sufficient for (µ, σ2), and also minimal sufficient as it is two dimensional. These
concepts are formally defined in Section 3.4.2.
3.3.4 Multivariate normal distribution
A p−dimensional random vector X = (X1, ..., Xp)′ has a p−variate normal distri-










(x− µ)′V −1(x− µ)
}
where µ = (µ1, ..., µp)
′ and V is the positive definite variance-covariance ma-
trix.
If X1, ..., Xp are independent univariate normal N(µi, σ
2
i ), then X ∼ Np(µ,V )
where µ = (µ1, ..., µp)
′ and V = diag(σ21, ..., σ
2
p) is a diagonal, positive definite
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Now suppose X is partitioned into X1 and X2, where X1 = (X1, ..., Xq) is a
q−dimensional multivariate normal with mean vector µ1 = (µ1, ..., µq) and covari-
ance matrix V1, and X2 = (Xq+1, ..., Xp) is a (p − q)−dimensional multivariate
normal with mean vector µ2 = (µq+1, ..., µp) and covariance matrix V2. Then we













where V12 and V21 are cov(X1,X2).
By standard theory of conditional probabilities, the conditional distribution of X1




∀x1 : f(x1) > 0 and ∀x2 ∈ R.
Hence, it can be shown that the conditional distribution of X1|X2 is q−dimensional
multivariate normal with conditional mean and variance given by µ1 +V12V
−1
2 (x2−
µ2) and V1 − V12V −12 V21, respectively. This can be written as
X1|X2 ∼ Nq(µ1 + V12V −12 (x2 − µ2),V1 − V12V
−1
2 V21).
3.3.5 Density of two univariate normals
The joint density of two univariate normals with equal means is required for the
derivation of point estimators in later chapters. This section gives detailed steps for
re-expressing this density to allow for more coherent reading in later chapters.
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2 − 2µx+ µ2) + σ21(y2 − 2µy + µ2)
]}
. (3.12)
Now expanding and factorising the terms inside the square brackets gives
σ22x
2 − 2µσ2x+ µ2σ22 + σ21y2 − 2µσ21y + µ2σ21
= µ2(σ21 + σ
2
2)− 2µ(σ22x+ σ21y) + σ22x2 + σ21y2




















































































































































































































































































































Using the identity v − av + bw
a+ b

















































































3.4 Statistical properties of an estimator
Point estimation involves inference about the unknown parameter θ. A random
quantity θ̂, defined as a statistic or estimator for θ, is obtained as a function of the
random sample X1, ..., Xn. We want this statistic to be as ‘close’ to the true value
as possible and there are several ways in which we can measure the reliability of this
statistic.
3.4.1 Bias and mean squared error
The following two properties are fundamental for assessing the accuracy and preci-
sion of an estimator.
Definition 3.4.1 (Bias). Suppose θ̂ is an estimator of θ. Then the bias of θ̂ is
defined by
b(θ̂) = E[θ̂]− θ.
Note that in general, bias is a function of θ.
Definition 3.4.2 (Mean squared error). The mean squared error (MSE) of θ̂ is
given by
MSE(θ̂) = E[(θ̂ − θ)2] = var(θ̂) + b2(θ̂).
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By Chebyshev’s inequality [Lindgren, 1993] it can be seen that for every ε > 0,
P (|θ̂ − θ|> ε) ≤ 1
ε2
E[(θ̂ − θ)2].
This indicates that if the mean squared error is small, then the chance that θ̂ is far
from θ is also small. Furthermore, if an estimator has zero bias then its MSE is its
variance. Hence, the MSE is a useful measure of the error of estimation, where a
desired estimator would be one with a small MSE.
3.4.2 Sufficiency and completeness
This section provides statistical concepts that are referred to throughout this thesis.
Definition 3.4.3 (Sufficiency). Suppose X1, ..., Xn is a random sample from X that
has density function fθ(x). Then a statistic T (X1, ..., Xn) is a sufficient statistic for θ
if the conditional distribution of X1, ..., Xn given T (X1, ..., Xn) is not a function of θ.
Definition 3.4.4 (Minimal sufficiency). If T (X1, ..., Xn) = fθ(T̃ (X1, ..., Xn)) for
every sufficient statistic T̃ (X1, ..., Xn), then T (X1, ..., Xn) is minimal sufficient.
Definition 3.4.5 (Completeness). A statistic T (X1, ..., Xn) is complete if, for any
function gθ(T (x1, ..., xn)), E[gθ(T (x1, ..., xn))] = 0 for all θ implies that
Pθ(g(T (x1, ..., xn)) = 0) = 1 for all θ.
Theorem 3.4.6 (Factorisation Criterion). A statistic T (X1, ..., Xn) is a sufficient
statistic for θ if there exists non-negative functions g and h such that,
fθ(x1, ..., xn) = gθ(T (x1, ..., xn))h(x1, ..., xn) ∀θ.
The following theorem and definition are useful for finding minimal sufficient statis-
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tics.
Theorem 3.4.7 (Lehmann-Scheffé). Suppose X1, ..., Xn is a random sample from
X that has density function fθ(x) and T (X1, ..., Xn) is both sufficient and complete
for θ. Then T (X1, ..., Xn) is the minimal sufficient statistic.
Definition 3.4.8 (Complete minimal sufficiency of exponential families). Suppose
X1, ...,Xn is a random sample from X which has a p−variate distribution with
parameter vector θ = (θ1, ..., θp), where the pdf of X is given by expression (3.7).
Then the statistic










is a complete, minimal sufficient statistic for θ.
If one-to-one transformations of T (X1, ...,Xn) exist then they are also complete suf-
ficient statistics, and are minimal sufficient if they are p−dimensional. An example
of this was given in Section 3.3.3.
In summary, a sufficient statistic can be found by the Factorisation Theorem. A
minimal sufficient statistic can be found through either the Lehmann-Scheffé Theo-
rem or by the theory of exponential families. These theorems combined are used in
the process of Rao-Blackwellisation, as described in the next section.
3.5 Minimum variance unbiased estimation
In point estimation, bias and efficiency of estimators are two properties considered
when searching for the best estimator. More than one unbiased estimator may exist,
and therefore criteria by which estimators may be compared for efficiency need to
be considered.
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Definition 3.5.1 (Unbiasedness). An estimator θ̂ for θ is unbiased if
E[θ̂] = θ ∀θ.
Definition 3.5.2 (Efficiency). Let θ̂1 and θ̂2 be two unbiased estimators for θ. If
MSE(θ̂1) < MSE(θ̂2) then θ̂1 is said to be more efficient than θ̂2 and thus a more
precise estimator.
A desirable estimator for θ is therefore one which is both unbiased and has smallest
variance among all unbiased estimators. This is formally known as the Uniformly
Minimum Variance Unbiased Estimator (UMVUE). Utilising the concepts of Suffi-
ciency (Definition 3.4.3) and Completeness (Definition 3.4.5), the following theorem
is used for deriving the UMVUE. However, it is important to note that as an unbi-
ased estimator may not necessarily exist, a UMVUE may not always exist.
Theorem 3.5.3 (Rao-Blackwell). If T is a sufficient statistic for θ and θ̂ is an
unbiased estimator of θ, then θ̃ = E[θ̂|T ] is an unbiased estimator of θ with variance
at most the variance of θ̂, that is, var(θ̃) ≤var(θ̂).
Proof. Unbiasedness follows from
E[θ̃] = E[E[θ̂|T ]] = E[θ̂] = θ
and for the variance it follows that
var(θ̂) = E[(θ̂ − E[θ̂])2]
= E[(θ̂ − θ̃)2] + E[(θ̃ − E[θ̃])2]
= E[(θ̂ − θ̃)2] + var(θ̃)
≥ var(θ̃).
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This is known as variance reduction or Rao-Blackwellisation and shows that θ̃ is an
unbiased and efficient estimator for θ. If T is a complete, sufficient statistic, that
is, if it is a minimal sufficient statistic, then θ̃ is the UMVUE for θ [Lehmann and
Scheffé, 1950].
Note, although a UMVUE has smallest variance among all unbiased estimators,





Time-to-event data may arise in various areas of research, from finance to engi-
neering to medical research, where interest may be to model the lifetime of an
electronic industrial component or the survival time of a patient in a clinical trial.
Therefore, depending on the context, over the past few decades, developments have
been made under various names, all with the same aim of modelling the time until
the event of interest occurs. These advancements have led to a large number of
textbooks on the topic, including Collett [2015], Kleinbaum and Klein [2012] and
Machin et al. [2006]. Modelling of time-to-event outcomes may vary from standard
parametric models such as Weibull survival times to more flexible parametric and
semi-parametric models such as the Cox proportional hazards model. As the focus
of this thesis is clinical trials, examples of time-to-event data will come from medical
research and the terms time-to-event and survival are used interchangeably.
This chapter introduces standard single stage statistical methods for the analysis of




Survival analysis is used to analyse data where the endpoint is a measure of time to
an event. The endpoint is typically referred to as the event time or survival time,
where time is measured from the time of origin, usually the time of entry into a
trial, until the time the event occurs. Although the term survival analysis indicates
death is the event of interest, other outcomes such as time to disease progression or
time to tumour recurrence may be analysed using the same methods. Regardless
of the type of event, the methods used are often referred to as survival analysis in
medical research.
Trials with survival time-to-event outcomes tend to be longer in duration as the
event of interest, such as death, typically takes longer to be observed. This is
commonly defined as Overall Survival (OS) in late phase oncology trials. Such an
outcome has a lower event rate and therefore a longer observation period is needed
such that a sufficient number of deaths are observed for adequate power.
Although this chapter focusses on single stage methods, for two-stage trials, a plausi-
ble short-term outcome may exist with a higher event rate, which may be considered
as a surrogate endpoint for the primary outcome measure at the interim analysis.
Progression Free Survival (PFS) is defined as the time from entry into a trial until
disease progression or death. Therefore, PFS has a higher event rate than OS and
is thus commonly considered a surrogate endpoint for OS. Utilising a short-term
surrogate endpoint may be desirable in cases with a long follow-up time, where the
time required to observe the expected events for OS at the interim analysis would be
operationally infeasible in terms of trial duration [Di Scala and Glimm, 2011].
Due to the time-to-event nature of the endpoint, the distribution of survival times
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tends to be highly skewed. This can be seen on a histogram plot of the survival
times, where a small proportion of events are observed in the right tail of the plot.
Therefore, time-to-event data are not typically symmetrically distributed but in-
stead may be positively skewed. Additionally, survival times may be censored if the
event of interest is not observed. This is described in the following section. Hence,
standard distributions available such as the normal distribution would not be ap-
propriate for such skewed and censored data. A key feature of survival analysis is
the ability to deal with censoring that is common in time-to-event data.
4.2.1 Censoring
If the event of interest is not observed, the survival time is said to be censored.
Censoring may occur for two reasons, either due to limited trial duration or if a
patient has been lost to follow-up.
Let T and C denote the continuous non-negative random variables associated with
survival and censoring times and t and c represent the observed survival and censor-
ing times, respectively. There are three types of censoring encountered in survival
analysis; namely, left censoring, right censoring and interval censoring. Left cen-
soring and interval censoring are not often observed in medical research and are
therefore not discussed in this section.
Right censoring occurs in survival studies where the true survival time exceeds the
observed survival time. For example, at the end of study or if a patient withdraws
from the trial, the event of interest occurs to the right of the point last known
to be event free. In this case, t remains unknown with t > c. The censoring
time distribution is assumed to be stochastically independent of the event time
distribution. This is an important requirement in survival analysis as it means the
reason for censoring is unrelated to the event of interest, and therefore any censoring
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is referred to as non-informative. Since right censoring is most commonly observed
in clinical trials with time-to-event data, the type of data considered in this thesis
is subject to right censoring.
4.2.2 Functions in survival data
The functions described in this section are based on Collett [2015] and for ease of
interpretation the event of interest is assumed to be death. The two core functions
in survival analysis are the survivor function, S(t), and the hazard function,
h(t). The survivor function measures the proportion of patients who are event free at
time t and therefore gives the probability of an individual surviving to time t. Recall
from Chapter 3, the probability density and probability distribution functions are
denoted by f(·) and F (·), respectively. Then the survival function is given by
S(t) = 1− F (t) = P (T ≥ t).
The hazard function is a conditional density given that an individual was event free




P (t ≤ T < t+ ∆t|T ≥ t)
∆t
. (4.1)





All of the above functions can be derived from one another using standard theory
of conditional probabilities as follows. The conditional probability in equation (4.1)
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can be written as
P (t ≤ T < t+ ∆t)
P (T ≥ t)
=
F (t+ ∆t)− F (t)
S(t)
.















since dSdt = −f(t). This implies that
S(t) = e−H(t)
and hence, inversely, the cumulative hazard function may be obtained from the
survivor function as
H(t) = − logS(t). (4.2)
4.2.3 Kaplan-Meier estimate of the survivor function
Generally, non-parametric methods are used in life sciences to estimate the survivor
function and hazard function as they do not require the form of the probability
density function to be specified, and therefore, make no assumptions about the
underlying distribution of survival times. An empirical estimate of the survivor
function may be found by the Kaplan-Meier (K-M) method, which estimates survival
probabilities at each event time.
Assume there are r distinct event times that are ordered t(1) < t(2) < ... < t(r), and











































Treatment group + +Experimental Control
Figure 4.1: Kaplan-Meier estimate of simulated Weibull survival times for two treat-
ment groups. Crosses indicate censored observations.
nj denote the number of patients at risk at time tj and dj denote the number of
patients who experience the event at time tj . Additionally, let R(tj) denote the set
of individuals alive and uncensored at a time prior to the jth ordered event time
tj . The probability of surviving through an interval [tj , tj+1) is then estimated by
(nj−dj)
nj
. If censored observations occur in this interval, they are assumed to occur
immediately after the event time tj so that censored patients are included in the
risk set, R(tj). Since events are independent for each individual, the Kaplan-Meier







for t ∈ [tl, tl+1) (l = 1, ..., r), where tr = ∞. The probability of survival in the
interval tj to tj+1 − ε, for small ε, is unity, so that a plot of Ŝ(t) against study
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time resembles a step function, as shown in the K-M plot in Figure 4.1. This is a
useful tool, which is frequently used to summarise and visualise survival curves for
a descriptive comparison of groups.
4.3 Hypothesis testing
4.3.1 Log-rank test
The K-M curve is an empirical estimate of the survival function which allows com-
parison of survival rates at a fixed time point. However, one of the most widely used
statistical tests for comparing survival distributions over the whole study period is
the non-parametric log-rank test.
Consider a two-arm trial with experimental treatment denoted by k = 1 and control
treatment denoted by k = 0. Suppose we are interested in inference on θ, the log
hazard ratio of the experimental treatment compared to control. Let njk denote the
number of patients at risk at time tj in group k and nj denote the total number
of patients at risk at time tj . Additionally, let djk denote the total number of
events observed at time tj in group k and dj denote the total number of events from
treatment groups k at time tj .
Summary data observed in each group at the jth death time are given in Table 4.1.
Under the null hypothesis of no difference in survival between treatment groups, it
is known that conditional on event times, number of patients at risk at these times
and the number of events at these times, djk has a hypergeometric distribution
Hyp(nj , njk, dj). Hence, by the marginal totals in Table 4.1 and by expression
















Control dj0 nj0 − dj0 nj0
Experimental dj1 nj1 − dj1 nj1
Total dj nj − dj nj
For convenience, let the proportion of patients at risk that are in group k at time





Then since djk has a hypergeometric distribution and we assume distinct death
times, that is, there are no tied events, following Section 3.2, the variance of djk can
be simplified to
vjk = pjk(1− pjk). (4.4)
The score statistic is the difference in observed and expected number of deaths





(dj1 − ej1). (4.5)






The square of this test statistic, divided by its variance, is thus chi-square dis-







This statistic is commonly used for testing differences in survival distributions of
two treatment groups as it allows for censored observations. Assuming the hazards
in each group are proportional and if the number of events is not too small, S
is approximately normally distributed with mean θV and variance V [Whitehead,
1997]. The proportionality of hazards is a core assumption in many survival analysis
methods and is discussed in Section 4.4.1.
4.3.2 Wilcoxon test
There are several variations of the log-rank test, one of which is the Wilcoxon test,










This test is similar to the log-rank test in that it compares the survivor functions
between two groups. However, it incorporates a weight of the total number of
patients at risk on the difference between observed and expected events. The factor
of nj ensures greater weight is assigned to early event times and less weight at times
when only a small number of patients remain in the risk set. Hence, this test is
more powerful when earlier differences are larger than late differences, since more
weight is applied to early event times.
In addition to the Wilcoxon test, other variations of weights may be used, such as
weighting by the proportion of the risk set [Tarone and Ware, 1977] or an estimate
of the survivor function [Peto and Peto, 1972].
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4.3.3 Stratified log-rank test
In cases where survival is expected to differ between subgroups of patients, it may be
desirable to perform a stratified log-rank test to control for the subgroup differences.
For example, in biomarker studies, a subpopulation with a positive biomarker may
be expected to respond better to treatment compared to patients with a negative
biomarker. More details on this setting are given in Chapter 7. In this case, the
log-rank test statistic is calculated for each subgroup separately and then summed
over all subgroups to give a stratified log-rank test statistic.
Let m denote the stratum over s strata, then the stratified log-rank statistic for








where Sm and Vm are the log-rank test statistic and variance computed for the
experimental treatment in each stratum m, as defined in equations (4.5) and (4.6),
respectively.
This is a more powerful test statistic when considering subgroups as it compares
the distributions of survival times in each stratum. Hence, provides a more precise
summary of treatment efficacy if there are true differences between the strata in
terms of hazard rate.
4.4 Estimation of the log hazard ratio
In survival analysis, the most commonly reported statistic for evaluating treatment
efficacy is the hazard ratio (HR). Recall, in this thesis the log HR is denoted by θ.
The methods described below for calculation of the log HR assume the hazard rates
in each group are proportional over time t.
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Let λ0(t) and λ1(t) denote the true hazard rates over time in the control and exper-







The log-rank test statistic given in expression (4.7) may be used to obtain an esti-





For a large number of events, this is approximately normally distributed with mean
θ and variance 1V .
Alternatively, an estimate of θ may be found by the quantities in Table 4.1. Let
Ok =
∑r
j=1 djk and Ek =
∑r
j=1 ejk denote the total observed and expected number








This gives an estimate of the relative death rates in the two groups. The log HR is
assumed to be constant over study follow-up and therefore assumes the hazard func-
tions are proportional over time. Under the null hypothesis of no survival difference
between the two groups, the log HR is equal to 0. Hence, if θ̂ is less than 0, the
hazard in the control group is larger than the hazard in the experimental treatment
group, which therefore indicates a beneficial treatment effect.
An adjusted log HR estimate may be obtained in a similar way for the stratified
log-rank test (4.8). As before, estimates for Okm and Ekm are obtained separately
for each treatment k in each stratum m and then summed over s strata to give a
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4.4.1 Proportional hazards assumption
Most survival analysis methods assume hazard rates are proportional over time for
all model covariates. However, this assumption may not always hold, for example,
if the experimental treatment is found to be better in terms of short term survival
while the control treatment is better in terms of long term survival. In this case,
the hazard rates for each treatment depend on time, and thus do not satisfy the
proportionality assumption. Modelling approaches described in the next section
assume proportional hazards and therefore it is important to check this assumption
holds before modelling.
A simple graphical check of proportionality may be to plot the log of the cumulative
hazard function (4.2) against log of time, that is, log(− log(S(t))) vs. log(t). If
the proportional hazards assumption holds, the lines should appear approximately
parallel. Additionally, time-dependent covariates may be incorporated to check for
proportionality when modelling.
4.5 Modelling approaches
Most modelling principles of survival data are similar to those for other types of
data, except survival data are generally modelled on the log-hazard scale. The two
most common approaches are either parametric models or semi-parametric models.
The former assumes some functional form for the baseline hazard, whereas the latter
makes no assumption about the shape of the baseline hazard function. This relaxed
assumption gives the most widely adopted model in survival analysis known as the
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Cox proportional hazards model.
4.5.1 Cox proportional hazards model
The most common model applied to time-to-event data is the semi-parametric Cox
proportional hazards (PH) model [Cox, 1972]. For an individual i (i = 1, ..., n),
let xi = (xi1, ..., xig) denote a vector of g predictor variables and β = (β1, ..., βg)
′
denote the associated vector of coefficients. Then the hazard function for the ith
individual can be modelled by
hi(t) = h0(t)e
β′xi , (4.12)
where h0(t) is the baseline hazard function and β
′xi is the linear predictor, also
known as the risk score or prognostic index for the ith individual. The baseline
hazard function is the hazard function for an individual with all covariate values
x = (0, ..., 0). Thus an estimate of the log HR (θ̂) for covariates xi relative to x = 0
is β̂.
The form of this model indicates that the covariates act multiplicatively on the
baseline hazard rate at any point in time and therefore implies the hazard functions
for all variables are proportional over time.
The most appealing feature of the Cox model is that it does not estimate the baseline
hazard function and therefore makes no assumption about the probability distribu-
tion of survival times. Hence, a semi-parametric approach is taken for parameter
estimation, where the partial likelihood is maximised to estimate the β parame-
ters.
Let δi denote the indicator for an uncensored survival time at ti and let R(ti) denote
the risk set at time ti for the i













In some cases it may be reasonable to assume the baseline hazard follows a specific
probability distribution. In such cases, a fully parametric survival model may be
fitted to give more precise estimates. The most common distributions considered in
survival analysis are the exponential and Weibull distributions.
The simplest case is when it is assumed that the hazard is constant over time.
In this case the hazard function can be modelled by h0(t) = λ for 0 ≤ t < ∞.
This therefore gives the exponential survivor function S(t) = e−λt with probability
density function of survival times f(t) = λe−λt. Thus, the exponential PH model
can be written as
hi(t) = λe
β′xi . (4.13)
Due to the constant hazard function, the exponential distribution has a ‘lack of
memory’ property such that
p(T > t) = p(T > t+ t0|T > t0)
for t0 > 0. Hence, the probability of surviving another t period is independent of
surviving up until time t0. This is an attractive feature of the exponential model,
however it is not often representative of medical data. In medical research it is
typical for the baseline hazard to vary with time, and therefore the constant hazard
function of the exponential model is not appropriate. A generalisation of this model
gives the most popular parametric survival model known as the Weibull model. This
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γ = 2γ = 3
Figure 4.2: Weibull hazard function for γ ∈ {0.5, 1, 1.5, 2, 3} with λ = 1.
allows the hazard function to vary with time as a power of t and thus provides a
more flexible form of the hazard function. This is given by h0(t) = λγt
γ−1. Assum-
ing survival times follow a Weibull distribution, the probability density function is
f(t) = λγtγ−1e−λt
γ
with survivor function S(t) = e−λt
γ
. Hence, the Weibull PH




The shape parameter γ allows the hazard function to vary with time. Hence, when
γ = 1, the Weibull model reverts to the exponential model. Examples of Weibull
hazard functions for different values of γ and λ = 1 can be seen in Figure 4.2.
For γ > 1 the hazard rate increases as γ increases, while for γ < 1, the hazard
decreases.
Since these models are fully parametric, model parameters, λ and γ, are estimated
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The multiplicative form of these models again implies the proportional hazards
assumption must be satisfied for model validity. For data with non-proportional
hazards, these models are not appropriate as the assumption of a constant hazard
ratio over time is violated. In this case, there are several more complex methods
which may be used that incorporate time-dependent covariates, such as stratified
Cox regression or flexible parametric modelling [Royston and Lambert, 2011].
In addition to the models presented in this section, other distributions may be




Unbiased estimation in seamless
phase II/III clinical trials with
normally distributed
outcomes
This chapter introduces methods of estimation for two-stage trials with normally dis-
tributed data that we will build upon in the next chapter. The first section describes
issues that arise in estimation when combining data across two stages. Specifically,
selection bias of naive maximum likelihood estimators is explored for various trial
scenarios. Previously suggested unbiased and efficient estimators are then described
for normally distributed outcomes. The chapter ends with a simulation study that
compares the properties of the naive and unbiased estimators.
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5.1 Setting
This chapter assumes the setting of a phase II/III clinical trial described in Section
2.4.1. As discussed, combining data from stages 1 and 2 may result in biased es-
timation of the treatment effect size, as stage 1 data are used for both treatment
selection as well as testing for treatment efficacy. This is because selection is made
on the basis of ordered effect sizes at the interim analysis, where the most efficacious
treatment is selected to take forward into stage 2. Therefore, early selection may
result in an overestimated treatment effect at the end of the trial. Using stage 2
data alone will yield an unbiased estimate of the treatment effect, but at the ex-
pense of losing information from stage 1. Thus, an ideal estimator would be one
which utilises all trial data while correcting for the potential bias due to treatment
selection.
The degree of selection bias varies depending on several factors such as the planned
sample size, the proportion of patients in each stage, the number of treatments
under investigation, and the true effect sizes for the selected and dropped treatments
[Bauer et al., 2010]. The influence of these factors on selection bias are discussed in
the following sections.
5.2 Notation
We use the notation in Bowden and Glimm [2008] for a two-stage phase II/III clinical
trial. Assume treatment arms in stage 1 are labelled k = 0, 1, ...,K, where k = 0
corresponds to the control treatment, with outcomes for each treatment normally
distributed with unknown mean µk and known common variance σ
2. Let ni denote
the number of patients allocated to each treatment arm in stage i = 1, 2. Let X̄k
denote the stage 1 sample means for treatment k such that X̄k ∼ N(µk, σ21), where
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σ21 = σ
2/n1. At the interim analysis, the treatment deemed most efficacious based
on a predefined criterion is selected, along with the control treatment, for further
analysis in stage 2. Let s (s ∈ {1, ...,K}) denote the index of the selected treatment
such that stage 2 sample means are denoted by Ȳj ∼ N(µj , σ22) for j ∈ {0, s}, where
σ22 = σ
2/n2. Let τ denote the information fraction available at the interim analysis,
which is defined by the ratio of the stage 1 sample size per group to the total sample
size per group, that is, τ = n1/n where n = n1 + n2. This is also referred to as the
‘selection time’.
5.3 Selection rule
At the end of stage 1, various interim adaptations may be applied before the trial
continues to stage 2. As mentioned, these may include, stopping early for futil-
ity or efficacy, modifying the total sample size, or selecting the best experimental
treatment. In this section, based on Kimani et al. [2013], we explore the impact of
treatment selection, where the treatment deemed most effective at the interim anal-
ysis is selected to continue in stage 2. For normally distributed outcomes, sample
means are used to assess treatment efficacy. At the interim analysis, stage 1 sample
means are ordered in increasing magnitude where the treatment with the maximum
observed mean is selected to continue in stage 2. Let X̄(1) > X̄(2) > ... > X̄(K)
denote the ordered stage 1 sample means, then the selected treatment s is such that
X̄s = X̄(1).
5.4 Maximum likelihood estimators
At the final analysis, interest lies in estimating the mean treatment difference θs =
µs − µ0 whilst utilising data from both stages of the trial. We can obtain a naive
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Maximum Likelihood Estimate (MLE) for each treatment group separately. This is
the weighted average of stage 1 and stage 2 data, which ignores treatment selection.
Let µ̂k denote the naive MLE for µk, k = {0, s}, such that
µ̂0 = τX̄0 + (1− τ)Ȳ0 (5.1)
and
µ̂s = τX̄s + (1− τ)Ȳs. (5.2)
Then the naive MLE for the mean treatment difference is given by
θ̂s = µ̂s − µ̂0. (5.3)
This is commonly referred to as a ‘naive’ estimator as it does not consider the
adaptation rule at the interim analysis. If the only interim adaptation is that of
treatment selection and there is no possibility of early stopping, then µ̂0 is unbiased
for the control treatment mean. On the other hand, for the selected treatment, µ̂s
is biased for µs due to the ordering and selection of X̄s. Subsequently, θ̂s is biased
for θs.
5.5 Selection bias
Selection bias is defined as the expected difference between the estimator and the
true mean treatment-control difference, that is, E[θ̂s − θs]. Several papers discuss
bias in estimation that arises from treatment selection where they have shown that
selection may lead to overestimation of the true mean difference [Bauer et al., 2010,
Bretz et al., 2009, Posch et al., 2005]. For example, if all experimental treatments
are equally effective then selecting a treatment that has the largest mean effect at
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the interim analysis will result in overestimating the mean difference at the final
analysis since it is selected only by chance. Therefore, this leads to a positively
biased estimator [Bauer et al., 2010].
Analytical expressions for bias and Mean Squared Error (MSE) have been given
by several authors. Bauer et al. [2010] show that treatment selection bias depends
on a combination of the number of experimental treatments, selection time and
variance of the sample means. Let φµ,σ2 and Φµ,σ2 denote the density and cumulative
distribution functions of a normal distribution N(µ, σ2), respectively. Then the
following expressions by Bauer et al. define the selection bias and MSE of the naive
estimator, given by equation (5.3), when the treatment with maximum mean is


























Φµj ,σ21 (x)dx+ (2− τ)σ
2/n. (5.5)
Expressions (5.4) and (5.5) demonstrate that bias and MSE depend on the selection
time τ , mean outcomes µk, number of treatments K, variance σ
2 and the sample
size n. Since τ is the ratio of the stage 1 sample size to the total sample size, from
the contribution of τ in the above expressions, we can conclude that bias and MSE
are maximum when selection is made at the final analysis, that is, when τ = 1. This
is commonly referred to as ‘post-trial selection’ [Bauer et al., 2010].
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Using expressions (5.4) and (5.5), we now assess the bias and root mean squared error
(RMSE) of the naive MLE for a range of values of τ and K for different scenarios
of the true mean effects µk. For each scenario we consider values of K ∈ {1, ..., 6}
treatment groups. Let the selection time 0 ≤ τ ≤ 1, such that the number of patients
in each treatment group in stage 1 is n1 = τn. A total of n = 100 patients per group
are assumed. However, to make results approximately independent of n, bias and
RMSE plots are given in units of σ
√
2/n. This therefore allows generalisation of
results to trials with different sample sizes in certain ranges.
5.5.1 Equal treatment means
First consider the setting where all treatment means are equal, and without loss
of generality let µk = 0 ∀ k. This is considered the worst case scenario where we
would expect greatest bias [Bauer et al., 2010]. Figure 5.1(a) shows the bias (top)
and RMSE (bottom) for θ̂s as a function of selection time, τ , for up to 6 treatment-
control comparisons. It can be seen that selection bias increases with selection time
(proportion of stage 1 patients). Hence, as expected, the maximum bias is observed
in the case of post-trial selection. Additionally, bias increases with the number of
experimental treatment groups K.
In terms of MSE, Figure 5.1(a) (bottom) indicates an increase in RMSE as the
number of treatments in a given trial increases. However, this increase is not as
steep as compared with selection bias (note the difference in scales). An explanation
for this is the square of the information fraction in the expression for the MSE in
equation (5.5). For K = 2, Figure 5.1(a) (bottom) shows that RMSE is equal to
that for K = 1. This is expected as we have assumed equal treatment means with a
common variance and Posch et al. [2005] show that selection between two normally
distributed outcomes with the same variance only depends on the effect size.
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K=1 K=2 K=3 K=4 K=5 K=6
Figure 5.1: Bias (top row) and RMSE (bottom row) depending on the number of experimental treatment arms K ∈ {1, ..., 6}
and the selection time 0 ≤ τ ≤ 1. Each column represents a different combination of treatment means, µk, k ∈ {0, ...,K}: (a)
µk = 0, (b) µ1 = 0.3 and µk 6=1 = 0, and (c) µk = 0.1k.
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5.5.2 Unequal treatment means
In the case of unequal treatment means, we assess the effect of the magnitude of the
treatment difference on selection bias. We consider two scenarios to assess the bias
and MSE for different values of τ and K.
In the first scenario we assume one uniquely superior experimental treatment with
treatment means µ1 = 0.3 and µk = 0 (k = 2, ...,K). Table 5.1 gives the probability
of selecting the treatment with the largest mean effect. For all values of K, it can be
seen that if one treatment is uniquely superior to all other experimental treatments,
then the probability of selecting this treatment is increased compared to the case of
equal means. Hence, as the probability of selection increases, selection bias reduces.
This can be seen in a comparison of Figures 5.1(a) and 5.1(b).
Furthermore, as we have seen in the previous section, the information fraction τ is
an important factor for selection bias. In Table 5.1 we can see that the probability
of correct selection increases as τ increases. For example, for a trial with two
experimental treatment arms, the probability of correct selection increases from
0.75 to 0.91 for τ = 0.2 to τ = 0.8. This is because an early selection time may lead
to premature data with reduced precision, which consequently reduces the chance
of correctly selecting the truly superior treatment.
In the second scenario we consider unequal treatment means µk = 0.1k for k =
{0, ...,K}. To assess the effect of τ in this scenario, Figure 5.1(c) shows a steady
increase in bias and RMSE until τ = 0.3, at which point bias and RMSE reach
a plateau for all values of K. Furthermore, in contrast to the scenario of equal
treatment means, where bias increases with K, in this scenario, bias is found to be
approximately equal for all values of K ≥ 4 for τ > 0.3. This is similar for RMSE.
In addition, a higher probability of selection is associated with a larger information
fraction τ , while an increase in the number of experimental treatments K leads to
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Table 5.1: Probability of selecting the truly most effective experimental treatment
for normally distributed outcomes. Treatment arms are denoted by k ∈ {0, ...,K},
where k = 0 denotes the control arm. A range of treatment means µk ∈ {0, ..., 0.6}
are considered for varying information fraction τ under 3 scenarios of equal effect
sizes, one superior treatment, and unequal effect sizes.
No. of treatment arms, K
τ Effect size 1 2 3 4 5 6
0.2 µk = 0 1 0.50 0.33̇ 0.25 0.20 0.16̇
µ1 = 0.3, µk 6=1 = 0 1 0.75 0.62 0.54 0.48 0.43
µk = 0.1k 1 0.59 0.47 0.42 0.40 0.39
0.5 µk = 0 1 0.50 0.33̇ 0.25 0.20 0.16̇
µ1 = 0.3, µk 6=1 = 0 1 0.86 0.77 0.70 0.65 0.61
µk = 0.1k 1 0.64 0.55 0.52 0.51 0.51
0.8 µk = 0 1 0.50 0.33̇ 0.25 0.20 0.16̇
µ1 = 0.3, µk 6=1 = 0 1 0.91 0.85 0.80 0.76 0.73
µk = 0.1k 1 0.67 0.60 0.58 0.58 0.58
reduced probability of selection (Table 5.1).
To further assess the effect of the magnitude of the treatment differences, we consider
the case of ‘post-trial selection’, where τ = 1 for a trial with K = 3 experimental
treatments. Figures 5.2 and 5.3 illustrate contours of selection bias and RMSE re-
spectively, in units of σ
√
2/n. The range of treatment means for µ2 and µ3 are given
along the x and y− axis, respectively, with µ0 = µ1 = 0 in all configurations.
In Figure 5.2, maximal selection bias is observed at the centre of the plot where
all treatment means are equal, that is, when µ1 = µ2 = µ3. As can be seen, bias
reduces as the difference in means increases. Hence, this reiterates that selection
bias depends on the size of the mean difference.
In terms of RMSE, for a trial with 3 experimental treatment groups, contours of
RMSE form an elliptical shape where again maximal RMSE is observed at the centre
where all treatment means are equal (Figure 5.3). As can be seen, RMSE decreases
with increasing difference in means.
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In conclusion, selection bias and MSE depend on the selection time τ , number of
experimental treatments K, the variance of the effect estimates, the size of the
treatment difference and the sample size.
Figure 5.2: Contours of selection bias for K = 3 and τ = 1
Figure 5.3: Contours of RMSE for K = 3 and τ = 1
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5.6 Unbiased estimation for normal outcomes
The MLE presented in expression (5.3) combines both stages of trial data to obtain
an estimator for the selected treatment effect. As we have seen, this estimator is
biased as stage 1 data are used for both treatment selection and estimation at the
end of the trial. It is possible to obtain an unbiased estimator using stage 2 data
alone, however the precision of this estimator would be compromised as it does not
utilise all trial data. Several methods that account for selection bias in estimation,
which utilise all trial data, are available for normally distributed outcomes. One
such method applies the Rao-Blackwell theorem to obtain unbiased and efficient
estimators conditional on various interim adaptations [Cohen and Sackrowitz, 1989,
Kimani et al., 2013]. This method is now described in detail.
As demonstrated in Section 5.5, estimation is conditional on the ranking of treat-
ment effects. Thus, when the selection rule is based on the observed effect size,
the naive estimator θ̂s is positively biased for θs, regardless of whether the trial is
able to stop early for futility. Several papers have addressed bias in estimation for
a two-stage setting with normally distributed outcomes. Some focus on bias correc-
tion methods in which bias-adjusted estimators are proposed based on an iterative
bias evaluation approach [Shen, 2001, Stallard and Todd, 2005], whilst others have
proposed unbiased estimators for various trial settings. These include, allowing for
unequal stagewise variances [Bowden and Glimm, 2008], allowing for early stop-
ping [Kimani et al., 2013], and allowing for correlated stage 1 statistics [Robertson
et al., 2016]. As this thesis is interested in unbiased estimators, the latter methods
are now explored in detail with the aim of providing a basis for work in the next
chapter.
Unbiased estimation in trials with treatment selection was first introduced by Cohen
and Sackrowitz [1989] where they developed a Uniformly Minimum Variance Condi-
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tionally Unbiased Estimator (UMVCUE) using the method of Rao-Blackwellisation,
as defined by Theorem 3.5.3. They assume independent, normally distributed treat-
ment means with equal variances and do not permit early stopping for futility or
efficacy. This method has been discussed and extended by Bowden and Glimm [2008]
and Kimani et al. [2013]. The former extend the Cohen and Sackrowitz [1989] esti-
mator to consider unequal variances and extend the selection rule to not only select
the most efficacious treatment but also the kth best treatment out of K.
Kimani et al. [2013] further extend these methods to incorporate an early stopping
futility boundary if no experimental treatment indicates sufficient efficacy at the
interim analysis, whilst also conditioning on the trial continuing to the second stage.
They derive a UMVCUE for µs and µ0 by calculating the expected values for Ȳs and
Ȳ0 conditional on sufficient and complete statistics. Hence, they give an unbiased
estimator for the most efficacious experimental treatment at the interim analysis,
conditional on continuing to the second stage with the possibility of stopping early
for futility. This estimator is now described with the aim to derive a UMVCUE for
θs. However, to allow comparison with estimators developed in later chapters, we
consider the scenario where the trial always continues to the second stage without
the possibility of early stopping.
5.6.1 A UMVCUE accounting for treatment selection
As mentioned, estimates from stage 2 data alone, Ȳs and Ȳ0, are unbiased but
inefficient for µs and µ0, respectively. Therefore, unbiased and efficient estimators
that combine both stage 1 and 2 data are sought. Since Ȳs is unbiased for µs,
using the Rao-Blackwell theorem a new unbiased and efficient estimator is defined
by µ̃s = E[Ȳs|Ts], where Ts is a sufficient and complete statistic. As before, let stage
1 treatment means be ordered by sample means, that is, X̄(1) > X̄(2) > ... > X̄(k)
and without loss of generality, let X̄(k) = X̄k. Then the selected treatment at the
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interim analysis is treatment 1 such that s = 1.
We are interested in the trial continuing to the second stage in order to derive the
UMVCUE at the end of the trial which pools stage 1 and 2 estimates. Let Q(X)
denote the observed ordering of the treatment means, that is, Q(X) = {X̄0, X̄1 >
... > X̄k}. We seek the sufficient statistic T1 given Q(X) for µ1 that combines both
stage 1 and 2 means for treatment 1.
Let I[Q(x)] denote the indicator function for Q(x) and P (µ) = Prob(I(Q(x)) = 1).
Then the joint density of (Ȳ0, Ȳ1, X̄) given Q(X), where X̄ = (X̄0, X̄1, ..., X̄K) is
given by














































, then using the result in expression (3.11)












































, then by Definition 3.4.3 and Definition 3.4.8, T1 =
(X̄0, X̄2, ..., X̄K , Ȳ0, Z1) is a sufficient and complete statistic for estimating µ1. Hence,
by Rao-Blackwellisation, the UMVCUE for µ1 is found by deriving E[Ȳ1|T1, Q].
Since E[Ȳ1|T1, Q] =
∫
ȳ1f(ȳ1|t1, Q)dȳ1 and f(ȳ1|t1, Q) = f(ȳ1,t1,Q)f(t1,Q) , we seek the den-
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sities f(ȳ1, x̄0, x̄2, ..., x̄K , ȳ0, z1|Q) and f(x̄0, x̄2, ..., x̄K , ȳ0, z1|Q).
By transformation of random variables, the density f(ȳ1, ȳ0, x̄|Q) (5.7) is trans-

























Similarly, the density f(x̄0, x̄2, ..., x̄K , ȳ0, z1|Q) is derived by transforming
f(ȳ1, ȳ0, x̄|Q) (5.7) into f(x̄, ȳ0, z1|Q), with Jacobian of the transformation equal to
1, and then integrating with respect to x̄1, as follows. The ordering of Q(X̄) implies
x̄1 > x̄2 and thus, by transformation of f(ȳ1, ȳ0, x̄|Q),






























































(µ̂1 − x̄2). Hence, from expressions (5.8) and (5.9), the
density required for the UMVCUE is
f(ȳ1|x̄0, x̄2, ..., x̄K , ȳ0, z1;Q) =
f(ȳ1, x̄0, x̄2, ..., x̄K , ȳ0, z1|Q)































Let L1 denote this limit of integration such that L1 =
σ2
σ1
(z1− σ2σ1 x̄2). Then using the
result of the expectation of a truncated normal (3.9), the UMVCUE for µ1 is
µ̃1 = E[Ȳ1|X̄0, X̄2, ..., X̄K , Ȳ0, Z1, Q] =
∫ L1
−∞








































The first term in equation (5.11) is the naive MLE for the selected treatment µ̂s
(5.2), and thus, the second term is the bias correction factor for overestimation of
the MLE.
For the control treatment, the UMVCUE for µ0 can be derived in a similar way.
The density of stage 1 and 2 sample means is given by






































and x̄′1 = (x̄1, ..., x̄K).
Expanding the terms in this density and using the result in expression (3.11), this












































, then by the factorisation criterion (Theorem 3.4.6) it
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follows that T0 = (X̄1, ..., X̄K , Ȳ1, Z1) is a sufficient and complete statistic for µ0.
Hence, the UMVCUE is found by E[Ȳ0|T0, Q] and so we seek the densities
f(ȳ0, x̄1, ..., x̄K , ȳ1, z0) and f(x̄1, ..., x̄K , ȳ1, z0). In order to derive these densities, we
follow similar steps to the derivation of densities (5.8) and (5.9), noting that x̄0 is
unbounded. The required densities are




































Thus, following expressions (3.8) and (3.9) of a truncated normal, the UMVCUE
for µ0 is















Hence, from expressions (5.11) and (5.16) an unbiased estimator for θs, accounting
for treatment selection is
θ̃s = µ̃s − µ̃0. (5.17)
As can be seen in expression (5.16), the UMVCUE for the control treatment is
equal to the naive estimator µ̂0. Hence, this indicates that bias in θ̃s can only
be attributed to the naive estimator for the selected experimental treatment µ̂s.
Furthermore, since no early stopping for futility is considered, µ̃1 is the same as the
Cohen and Sackrowitz [1989] estimator.
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5.7 Simulation study
To compare the properties of the naive MLE with the conditionally unbiased es-
timator described in the preceding section from Kimani et al. [2013], a simulation
study is conducted with three scenarios. The first scenario assumes equal treatment
means, the second assumes one experimental treatment is truly superior to all other
experimental treatments and the third scenario assumes unequal treatment means.
In each scenario, we consider a trial with 4 treatment groups and set the total num-
bers of patients per arm to n = 400 for 500,000 replications. Recall the number
of patients in stage 1 is defined by n1 = τn, where τ denotes the selection time.
For each scenario, Figure 5.4 shows bias and RMSE in units of standard error of
the naive MLE θ̂s and the conditionally unbiased estimator θ̃s, given by expressions
(5.3) and (5.17), respectively.
For the case of equal treatment means, similar properties of the naive estimator and
UMVCUE have been illustrated by Kimani et al. [2013]. However, since they are
primarily interested in the influence of a futility boundary, their study explores only
small effect sizes with up to 5 experimental treatment arms for a range of futility
stopping boundaries. Due to the futility boundary, their results indicate a larger
bias in the naive estimator compared to results shown here for the case of equal
treatment means in Figures 5.1 and 5.4, as these do not consider early stopping
for futility. We therefore examine properties of the estimators for not only equal
treatment means, but also for unequal treatment means and a range of experimental
treatment arms with small to large effect sizes, thus adding to the results in Kimani
et al. [2013].
Bias plots (Figure 5.4, top row) confirm the new UMVCUE has zero bias for all
selection times, in all cases. In terms of RMSE (Figure 5.4, bottom row), for the
case of equal means, it can be seen that the RMSE for θ̃s increases with selection
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time with a particularly steep increase for selection time above 0.8. As θ̃s is unbiased,
its RMSE is its variance for all selection time, which is partly influenced by the bias
correction term. Therefore, this increase in RMSE for later selection time is partly
due to the more variable stage 2 estimate.
Now considering the case when one treatment is truly more effective than all other
experimental treatments, Figure 5.4 shows that the UMVCUE RMSE approaches
the MLE RMSE. This is because the correction term in the UMVCUE tends to zero
as the difference between the selected and second largest mean increases. In the
case of unequal means, the UMVCUE has a larger RMSE compared to the MLE
with a gradual increase observed with selection time.
Hence, as similarly shown by Kimani et al. [2013] for the case of equal treatment
means, the UMVCUE has favourable properties in terms of bias and RMSE for
early selection times, with a steep increase in RMSE observed for late selection
times. In contrast, we have shown that when all treatment means are different, the
increase in RMSE for late selection times is not as steep compared with the case
of equal means. Furthermore, when there is one superior mean, the RMSE of the
naive and unbiased estimators are comparable for all selection times for the case of
4 experimental treatment arms. We have additionally shown that bias in the naive
estimator is overall smaller when there are unequal treatment means or when only
one treatment is the most effective compared to the case of all equal means.
These results highlight that depending on the selection time and mean effect size, a
trade-off of bias and RMSE should be considered; as a small amount of bias in a more
precise estimator may be preferable to a larger MSE in an unbiased estimator.
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MLE (θ̂s) UMVCUE (θ
~
s)
Figure 5.4: Bias (top row) and RMSE (bottom row) in units of σ
√
2/n of θ̂s and θ̃s for the scenario of 4 experimental treatment
arms. Plots show the average of 500,000 simulations for each value of the selection time τ . Each column represents a different
combination of treatment means µk (k = 1, ..., 4): for equal means, µk = 0; one superior mean, µ1 = 0.3 and µk 6=1 = 0; and
unequal means, µk = 0.1k.
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5.8 Conclusion
This chapter presented methods for unbiased estimation of normal outcomes follow-
ing treatment selection in seamless phase II/III clinical trials. Properties of the naive
maximum likelihood estimator were explored for various trial scenarios, including a
range of effect sizes, number of experimental treatment arms and selection times.
It was shown that existing methods for unbiased and efficient estimation utilise the
Rao-Blackwell theorem to derive uniformly minimum variance unbiased estimators,
conditional on treatment selection. A simulation study comparing an unbiased esti-
mator with the naive estimator indicated that UMVCUEs are desirable for certain
scenarios, where a trade-off of bias and RMSE should be considered.
Since these methods assume uncorrelated stage 1 and stage 2 data, the estimators
described in this chapter are not appropriate for use in the analysis of time-to-event
data with treatment selection. The following chapter therefore builds on the work
in this chapter to address the issues with time-to-event data analysis in seamless




selection bias and correlation in
seamless phase II/III clinical
trials with time-to-event data
Despite methods of estimation described in the previous chapter correcting for se-
lection bias in the case of normally distributed outcomes, additional challenges arise
when analysis is based on time-to-event data. This chapter aims to develop un-
biased estimators accounting for treatment selection for time-to-event outcomes in
seamless phase II/III clinical trials.
The first section introduces the setting and describes the issues with analysis of time-
to-event data in two-stage trials. This is followed by a simulation study to assess
the degree of selection bias for different trial scenarios and thus motivate the need
for unbiased estimators. The following section describes the concept of independent
increments for use in subsequent sections where asymptotically unbiased estimators
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are derived for time-to-event outcomes. The properties of the estimators developed
are then presented by simulation for various trial scenarios. This chapter concludes
with a summary on estimation correcting for treatment selection bias and correlation
in seamless phase II/III clinical trials with time-to-event data.
6.1 Setting
As described in Section 2.4.1, seamless phase II/III clinical trials consist of two
distinct stages with an interim analysis conducted part-way through the trial. In
stage 1, patients are recruited to K experimental treatment arms plus a control arm.
At a predefined point in time, an interim analysis is conducted to select the most
efficacious experimental treatment based on a predefined selection rule.
Figure 6.1 depicts the possible outcomes for time-to-event endpoints in this two-
stage setting. During stage 1, patients may experience the event of interest (black
circle, e.g. patient 1) or they may be censored if they are either lost to follow-up
(white circle, e.g. patient 2) or yet to experience the event of interest, in which case
they are still in the trial at the time of interim analysis (e.g. grey circle, patients
3 and 4). If the latter occurs, then follow-up of these patients continues in stage 2,
where they either go on to experience the event of interest (e.g. patient 3) or are lost
to follow-up (e.g. patient 4). In this thesis, such cases, where follow-up continues
in stage 2, are referred to as delayed events.
In stage 2, new patients are recruited to the selected experimental treatment and
control group. Again, these patients may experience the event of interest before the
final analysis (e.g. patient 5) or may be censored at the time last known to be event
free if they are either lost to follow-up (e.g. patient 6) or do not experience the
event at the time of final analysis (e.g. patient 7). At the end of the trial, interest













Figure 6.1: Example of survival data in a two-stage clinical trial. Black circles
denote an event, and grey and white circles denote censored observations at the
interim and final analysis, respectively. Tinterim and Tfinal denote the calendar time
of the interim and final analysis, respectively.
trial.
With time-to-event data, a patient’s survival time is defined as the minimum of the
observed censoring and event times. At the interim analysis, the stage 1 estimator
is based on data accrued up until the time of interim analysis for all experimental
treatment and control arms. At the final analysis, the stage 2 estimator is based
on all accumulated data in the trial for the selected experimental treatment and
control arms. Defining the stage 2 estimator in this way leads to correlated stage 1
and 2 data. This is due to delayed events as the stage 2 estimator consists of patients
recruited in stage 1. Although defining the stage 2 estimator to be based only on new
patients followed up in stage 2 would eliminate this correlation, it would also ignore
the additional follow-up of stage 1 patients which would be an inefficient use of data.
Hence, additional follow-up of stage 1 patients is included in the analysis but the
common assumption of independence as with normally distributed data is violated.
This therefore may result in a biased estimator at the end of the trial.
Furthermore, unlike the standard setting with normally distributed outcomes, treat-
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ment effects are quantified by the relative difference of hazards in the experimental
group compared to the control group, rather than the absolute mean difference.
Hence, when analysis is based on semi-parametric approaches, such as Cox regres-
sion analysis described in Chapter 4, current methods cannot be applied directly as
estimates are correlated and not normally distributed.
Due to the added complexities in the analysis of time-to-event data described here,
the main limitations of the estimators discussed in the previous chapter for appli-
cation to time-to-event to event data are now described. The Bowden and Glimm
[2008] estimator accounts for selection but does not assume correlation within and
between stages. The Kimani et al. [2013] estimator is similar to the Bowden and
Glimm estimator in that it accounts for selection, ignoring within-stage and between-
stage correlation, but additionally allows for early stopping. The Robertson et al.
[2016] estimator accounts for selection and correlation within stage 1 but does not
assume correlation between stages. In addition, all of these estimators assume data
are normally distributed with treatment effect sizes ordered in increasing magni-
tude. Therefore, by extension of these methods, new estimators are developed in
this chapter that account for treatment selection bias in the analysis of two-stage
time-to-event data. Development of these estimators first focusses on extension of
the Kimani et al. [2013] estimator, where separate control arms are assumed for
each experimental treatment arm in Section 6.7. Then the work by Robertson et al.
[2016] is considered with an estimator assuming a common control arm derived in
Section 6.8.
6.2 Selection rule
Clinical trials with time-to-event endpoints are generally event driven which means
they are designed with the expected number of events as opposed to number of
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patients. Therefore, in contrast to the previous chapter, for time-to-event data the
information fraction, τ , depends on the number of events. Let d denote the total
number of events that occur at the interim analysis across all experimental treatment
and control arms and D denote the total number of events at the final analysis for
the entire trial. Then the information fraction is defined by τ = dD .
Let θk denote the true log HR for experimental treatment k (k = 1, ...,K) and θ̂ik
denote the estimator for θk in stage i (i = 1, 2). At the interim analysis, we consider
a selection rule similar to that in Section 5.3. However, as treatment efficacy is now
quantified by the log HR, the most efficacious treatment is defined as that which has
the smallest observed log HR. Hence at the interim analysis, treatments are ordered
in decreasing magnitude of effect size such that the estimated log HR of the selected
experimental treatment is denoted by θ̂1s = min{θ̂1k}, s ∈ {1, ...,K}.
6.3 Simulation study assessing bias of the naive estima-
tor
As we are interested in unbiased estimation, a simulation study is conducted to
investigate the degree of selection bias of the naive estimator θ̂s calculated at the
end of the trial. We assess the influence of the number of experimental treatments,
as well as selection time for three scenarios of effect sizes. The selection time is
based on the information fraction τ as defined in the preceding section. Up to
K = 6 experimental treatments are considered with τ ∈ {0.1, ..., 0.9}. A total of
n = 1500 patients are assigned to the control arm and each experimental treatment
arm k (k = 1, ...,K). The target number of events at the final analysis is defined as
D = 900 such that the number of events at the interim analysis in each scenario is
defined by d = τD. As described in Chapter 4, different distribution functions may
be utilised that best describe survival times. Since the Weibull density function has
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been shown to have the most flexible form, which allows the hazard to vary with
time, we assume survival times follow a Weibull distribution.
Selection bias and RMSE of the naive estimator θ̂s are calculated from 10,000 sim-
ulated studies for each τ . Selection bias for the selected treatment s is calculated
as the mean of the differences in the estimated log HR and the true log HR, that
is, θ̂s − θs. The MSE is calculated as the mean of the squared differences between
θ̂s and θs. Recall, since θk < 0 (k = 1, ...,K) implies superiority for treatment k,
a negative bias implies a positively biased estimator, that is, θ̂s overestimates the
true treatment effect.
6.3.1 Equal log HRs
Two scenarios of equal log HRs are investigated. The first considers the null case
where all experimental treatments are equally ineffective, where θk = 0 (k =
1, ...,K). Event times, Ej , are simulated for each patient j = 1, ..., n in control
group c and treatment group k (k = 1, ...,K) from a Weibull distribution with rate
and shape parameters set to λc = λk = 0.15 and γc = γk = 2.5, respectively. Addi-
tionally, censoring times, Cj , are simulated for the control and treatment arms from
Weibull(λc/1.5, 1) and Weibull(λk/1.5, 1), so that a patient’s survival time at the
point of analysis is defined as the minimum of the simulated event and censoring
times, that is, min{Ej , Cj}. An event is assumed to occur if Ej < Cj , and thus at
the time of analysis, if a patients survival time is greater than the calendar time of
analysis, the event is defined as censored.
The second scenario assumes all treatments are equally effective with θk = −0.22
∀k; this equates to a HR of 0.8. In this case, event and censoring times are simulated
as described above with Weibull parameters λc = 0.15, λk = 0.12 and γc = γk =
2.5.
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At the interim analysis, an estimate of the log HR, θ̂1k, is computed from the log-
rank score statistic for each treatment group at each selection time τ . Following
the selection rule in Section 6.2, the treatment with the smallest estimated log HR,
θ̂1s, is deemed most efficacious and is thus selected. Survival times for additional
patients are then simulated to this selected treatment arm and control arm. The
final analysis is conducted after a total of D = 900 events are observed in the entire
trial, that is, after a total of D(1− τ) new stage 2 events on the selected treatment
and control arms. At the final analysis, an overall estimate of the log HR for the
selected treatment is calculated from all data accrued in the trial. This is denoted
by θ̂s and is referred to as the naive estimator as it does not adjust for treatment
selection at the interim analysis or both the correlation between stage 1 estimates
and the correlation due to censored observations at the interim analysis.
Figure 6.2(a) shows the bias (top) and RMSE (bottom) of the estimated log HR, θ̂s,
as a function of selection time for up to 6 treatment groups, where all treatments
are assumed equally ineffective. It can be seen that as the number of treatment
comparisons increases, that is as K increases, selection bias and RMSE of the log
HR increases with selection time. This is analogous to selection bias in the naive
estimator for normally distributed outcomes (see Figure 5.1(a)). Hence, the naive
estimator of the selected treatment overestimates the true treatment effect due to
selection at the interim analysis. As expected for the case of one experimental
treatment, since no selection is made, the naive estimator is unbiased for all selection
times (solid line).
Figure 6.2(b) shows bias and RMSE for the scenario of equally effective treatments
(θk = −0.22∀k). As compared to scenario (a), a similar pattern of an increase in
bias as the number of experimental treatments increases is observed, with bias also
increasing with selection time for K ≥ 2. However, the magnitude of bias is overall
smaller than that for the scenario of equally ineffective treatments. Additionally,
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for K = 1, we would expect zero bias for all selection time since there is no bias
attributed to treatment selection. However, as can be seen by the solid line, there
is a small amount of bias for all selection times, which indicates the naive estimator
underestimates the true log HR. This is the inherent bias due to the normal ap-
proximation of the log-rank score statistic used in estimation. Therefore, this bias
serves as a benchmark for the bias due to the asymptotic normality assumption
and thus, asymptotically unbiased estimators developed later in this chapter, which
address the problem of selection bias, are expected to be only as biased as this naive
estimator.
6.3.2 Unequal log HRs
Now consider the case where one experimental treatment is superior to all other
experimental treatments. Data assuming Weibull survival times are simulated as
described in Section 6.3.1 with parameters λc = 0.15, λ1 = 0.12, λk = 0.15 and
γc = γ1 = γk = 2.5, for k ∈ {2, ..., 6}. This assumes the most effective experimental
treatment has a true HR of 0.8.
Plots of bias (top) and RMSE (bottom) are presented in Figure 6.2(c). For the case
where K = 1, a small underestimation can be seen when selection is made early in
the trial. This is similar to that observed for Scenario (b), which we believe is due to
the normal approximation of the log-rank score statistic. However, for K ≥ 2, since
there is a clear superior treatment, selection bias in comparison to scenarios (a) and
(b) is considerably smaller for all values of K and τ , as expected. In particular, bias
increases with the number of experimental treatments, however it is approximately
constant for all selection times.
For all scenarios, RMSE increases with the number of experimental treatments. Ad-
ditionally, a gradual increase in RMSE is observed for increasing selection time, with
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Figure 6.2: Bias (top row) and RMSE (bottom row) of the naive estimator for K ∈ {1, ..., 6} treatment groups and selection time
τ ∈ {0, ..., 0.9} from 10,000 simulations. Each column represents a different combination of effect sizes: (a) θk = 0 ∀k ∈ {1, ...,K},
(b) θk = −0.22 ∀k ∈ {1, ...,K}, and (c) θ1 = −0.22 and θk = 0 ∀k ∈ {2, ...,K}.
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a steeper increase observed for later selection times. This is due to the correlation
between stage 1 and stage 2 data, as later selection times correspond to a larger
information fraction, which means a greater proportion of events from patients re-
cruited in stage 1 are included in the final estimate. This correlation therefore needs
to be accounted for in order to obtain an efficient estimator, particularly for later
selection times.
In summary, this simulation study has shown that the naive estimator is biased
due to both treatment selection at the interim analysis and the correlation between
stage 1 and stage 2 data. In particular, the naive estimator will overestimate the true
effect size. However, in the case of one experimental treatment, the naive estimator
underestimates the effect size due to the normality assumption of the log-rank test
statistic. Hence, in addition to the inherent bias of the normal approximation, bias
and RMSE for time-to-event outcomes depend on treatment selection at the interim
analysis and correlation between stage 1 and stage 2 data.
6.4 Independent increments structure
An increment estimate, computed as the difference between the interim and final
analysis estimates based on log-rank score statistics, is assumed to be independent
and normally distributed [Wassmer, 2006]. Thus, defining such a estimate ensures
independence of stagewise estimates, where the interim estimate is based on all data
accrued up until the time of interim analysis, and the final estimate is based on all
data accrued in the entire trial up until the final analysis.
Tsiatis [1982] first introduced the concept of independent increments for testing
of censored survival data for the case of one experimental treatment compared to
a control. He assumed the setting of one interim analysis conducted for assess-













Figure 6.3: Example of survival data in a two-stage clinical trial. Black circles
denote an event, and grey and white circles denote censored observations at the
interim and final analysis, respectively. Tinterim and Tfinal denote the calendar time
of the interim and final analysis, respectively. Tfollow denotes the calendar time of
maximum follow-up for patients recruited in stage 1.
score test is multivariate normal with independent increments when patients are
recruited randomly during the trial. Use of the independent increment structure
for censored time-to-event outcomes has since been beneficial for hypothesis testing
with time-to-event data. However, papers including Bauer and Posch [2004] and
Jahn-Eimermacher and Ingel [2009] have highlighted the potential limitations of
this assumption in adaptive trials.
More recently, methods to ensure independence of stagewise test statistics, primarily
for the problem of multiple testing in two-stage survival trials have been proposed
by several authors including Di Scala and Glimm [2011], Jenkins et al. [2011] and
Irle and Schäfer [2012]. As this thesis focusses on treatment effect estimation using
the log-rank score statistic, these methods for multiple hypothesis testing are only
discussed briefly in order to highlight the concepts that will be used for point estima-
tion in subsequent sections. A comprehensive discussion on group sequential tests
and adaptive design methodology for hypothesis testing can be found in Jennison
and Turnbull [2000], Wassmer and Brannath [2016] and Whitehead [1997].
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The main requirement that has been highlighted in the literature is that design
modifications must be independent of the primary outcome at the interim analysis,
in order to avoid the possibility of predicting survival of the remaining patients at
risk [Jenkins et al., 2011]. This is because information from patients with delayed
events may be correlated with the survival time at the final analysis. This means that
at the final analysis, the additional follow-up of patients with delayed events at the
interim analysis must be prefixed in order to ensure the variance-covariance matrix
of the test statistics remains unchanged [Di Scala and Glimm, 2011]. Therefore,
we define Tfollow to be the maximum follow-up time for patients recruited prior to
Tinterim, as illustrated in Figure 6.3. This implies that any events that occur after
Tfollow for patients recruited in stage 1 are effectively ignored as survival times are
censored at Tfollow, for example, Figure 6.3, patient 4. Hence, the choice of Tfollow
needs to be tailored for each trial, as it would not be desirable to pre-specify Tfollow
to allow many extra events from stage 1 patients that were censored at the interim
analysis after Tfollow in the case where all events for patients recruited in stage 2 are
observed well before observing the pre-specified extra number of events from stage
1 patients. Conversely, pre-specifying few extra events from stage 1 patients, risks
losing information that would be obtained from the censored observation.
6.5 Overview of available methods for analysing time-
to-event data in seamless phase II/III clinical tri-
als
There is vast literature available which addresses the multiplicity problems for time-
to-event data. See, for example, Xi et al. [2016] for an overview of methods for
multiplicity issues in cancer clinical trials. Since asymptotic normality of the log-
rank score statistic is a well known assumption for large samples, the independent
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increments structure has allowed group sequential hypothesis testing to be based on
the log-rank test [Desseaux and Porcher, 2007, Jahn-Eimermacher and Ingel, 2009,
Schäfer and Müller, 2001, Wassmer, 2006].
As decribed in the previous section, we utilise the independent increments structure
with a prefixed follow-up time for delayed events. For hypothesis testing based on
the standardised log-rank test statistic, Di Scala and Glimm [2011] give the joint
distribution of a group sequential log-rank test for a two-stage two-arm trial with cor-
related time-to-event outcomes. They use the independent increments assumption
to obtain an independent increments covariance structure for the joint distribution
of stage 1 and 2 statistics. Although the use of independent increments has only
been considered for hypothesis testing in group sequential designs, their use may be
extended to point estimation based on the log-rank score statistic. Therefore, the
joint structure of the correlated test statistics is now described, as this concept will
be used for the derivation of point estimators in Sections 6.7 and 6.8.
6.5.1 Joint distribution of log-rank test statistics
As before, let θk denote the log HR for treatment k (k = 1, ...,K) compared to
control. The score statistic given in Section 4.3.1 may be used to obtain an estimate
of the log HR. This is the sum of the difference of the observed and expected events
summed over all event times in the trial. As we are considering a two-stage trial, at
the interim and final analyses, a log-rank statistic is now computed for each stage
based on all accumulated data at the end of each stage i (i = 1, 2). For now, we
assume all treatment arms are continued into the second stage.
Data for each experimental treatment and control arm at the jth death time are
summarised in Table 6.1. For distinct event times ri in stage i, the number of
deaths that occur in group k at time tj (j = 1, ..., ri) is denoted by djk. It is known
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No. alive No. at risk
Control dj0 nj0 − dj0 nj0
1 dj1 nj1 − dj1 nj1





K djK njK − djK njK
that the conditional distribution of djk given r1, r2 and (dj0 +djk) is hypergeometric










(djk − ejk). (6.1)
As mentioned in Section 4.3.1, the asymptotic distribution of Sik is normal with
mean θkVik and variance Vik, which is the sum of the variance of djk over all distinct






















This statistic is most commonly used for group sequential hypothesis testing since it
is standard normal under the null [Di Scala and Glimm, 2011, Irle and Schäfer, 2012,
Jenkins et al., 2011]. For large samples the variance is approximately a quarter of




At the interim and final analyses, each experimental treatment is compared to the
common control arm, which means estimates at each analysis are correlated. This
is referred to as within-stage correlation. Let V1,k,l denote the covariance of stage









where φj = pjkpjl is the correlation of the score statistics.
Additionally, as mentioned, delayed events from stage 1 patients cause stagewise
statistics, Z1k and Z2k, to be correlated. This correlation is denoted by ρk and
is obtained as follows. It is known that, cov(S1k, S2k) = V1k and let ψ1,k,l denote
cov(S1k, S1l) =
∑r1
j=1 φj . Then























































































1 V1,1,2 V1,1,3 · · · V1,1,K ρ1 ρ2V1,1,2 ρ3V1,1,3 · · · ρKV1,1,K
V1,1,2 1 V1,2,3 · · · V1,2,K ρ2V1,1,2 ρ2 ρ2V1,2,3 · · · ρKV1,2,K











V1,1,K V1,2,K V1,3,K · · · 1 ρKV1,1,K ρKV1,2,K ρKV1,3,K · · · ρK
ρ1 ρ2V1,1,2 ρ3V1,1,3 · · · ρKV1,1,K 1 V2,1,2 V2,1,3 · · · V2,1,K
ρ2V1,1,2 ρ2 ρ2V1,2,3 · · · ρKV1,2,K V2,1,2 1 V2,2,3 · · · V2,2,K
















6.5.2 Stage 2 increment statistics
Now in order to apply group sequential methods available for normally distributed
data, stage 1 and stage 2 statistics need to be uncorrelated. As described previously,
a well known approach for eliminating this between-stage correlation is to utilise the
independent increments assumption. This states that, by linear transformation, a
new statistic denoted by Z̃2k is approximately normal with mean θk
√
V2k − V1k and
variance 1 such that cov(Z1k, Z̃2k) = 0 [Di Scala and Glimm, 2011]. This is derived
as follows.
The increment score statistic is defined as S̃2k = S2k − S1k which is normally dis-












so E(Z̃2k) = θk
√
V2k − V1k and var(Z̃2k) = 1 and hence Z̃2k ∼ N(θk
√
V2k − V1k, 1).
It follows, by linear transformation of the multivariate normal distribution (6.7),






































1 V1,1,2 · · · V1,1,K 0 0 · · · 0









V1,1,K V1,2,K · · · 1 0 0 · · · 0
0 0 · · · 0 1 V ∗2,1,2 · · · V ∗2,1,K























The independent increments structure for the standardised statistics described in
this section has allowed group sequential hypothesis testing to be based on the log-
rank test [Schäfer and Müller, 2001, Wassmer, 2006]. However, there are a lack
of methods focusing on estimation following two-stage trials with survival data.
The following sections show how the methods described above can be adapted and
incorporated for developing point estimators based on the log-rank test statistic for
two-stage survival trials.
6.6 Derivation of the joint density of stagewise log HRs
Since we are interested in estimating the log HR, θk (k = 1, ...,K), we re-write stage





V2k − V1k. Let θ̂1k denote the new stage 1 statistic and θ̃2k
denote the new stage 2 increment statistic. Then θ̂1k =
Z1k√
V1k
= S1kV1k is asymptotically















Let σ1,k,l and σ2,k,l denote the covariance of (θ̂1k, θ̂1l) and (θ̃2k, θ̃2l), respectively.
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Then from expressions (6.4) and (6.9), it follows that






















(V2k − V1k)(V2l − V1l)
.
The correlation between stage 1 statistics is therefore








V1kV1l = V1,k,l. (6.11)
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Now assuming the trial always continues with treatment 1, and thus equivalently
dropping treatments k = 2, ...,K, the density for the stage 1 statistics and the stage
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This density can now be extended for developing point estimators based on the log-
rank test statistic for two-stage survival trials that account for treatment selection
and correlation. For treatment selection, without loss of generality of selecting
treatment 1, since the test statistics should not change with treatment selection
[Di Scala and Glimm, 2011], we must fix both the number of events from new
patients recruited in stage 2 and the number of delayed events from patients recruited
in stage 1 but who continue follow-up in stage 2, for the selected treatment and
control arms. In addition, the total number of stage 1 events across all arms must
also be predefined. Furthermore, since treatment 1 is selected as the apparently
most effective treatment at the interim analysis, the expected value of the stage
2 increment, θ̃21, is not smaller than θ1, since at the final analysis the estimated
treatment effect, including delayed events, would be expected to underestimate the
true treatment effect due to the overestimation at the interim analysis. This means
that result (6.12) is unchanged irrespective of the selection, except for the index of
the stage 2 log HR, and thus satisfies the independent increments structure.
6.7 Bias correction with separate control arms
To compare a similar setting for time-to-event data to normally distributed data,
a uniformly minimum variance conditionally unbiased estimator (UMVCUE) is de-
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rived in this section following the estimator described in Section 5.6.1 from Kimani
et al. [2013]. The assumptions of their estimator are that data are normally dis-
tributed, which means stagewise estimates are independent, and that the treatment
selected is that with maximum observed efficacy. Additionally, since data are nor-
mally distributed, treatment means are calculated for the control group and each
experimental group separately, which means stage 1 estimates are independent. Like
them, in this section, we consider the case of uncorrelated stage 1 estimates by as-
suming a separate control arm for each experimental treatment arm, but unlike
them, we allow for stage 1 and 2 estimates to be correlated by continuing follow-up
of censored patients at the interim analysis.
An asymptotically UMVCUE is now derived that is appropriate for time-to-event
data that directly estimates the log HR for the selected treatment. In order to
correct for the correlation between stagewise statistics, the UMVCUE utilises the
independent increments assumption where the stage 2 variance, σ221, is the variance
associated with the stage 2 increment estimate, as described in Section 6.6. Addi-
tionally, as mentioned, in order to maintain independence between stage 1 estimates,
in this section, separate control groups are assumed and this assumption is explored
further in the next section.
Consider a trial with K experimental treatment arms and a separate control arm for
each experimental treatment arm. As per the selection rule defined in Section 6.2,
let Qs denote the event that θ̂1(1) < θ̂1(2) < ... < θ̂1(K). Without loss of generality
assume θ̂1(k) = θ̂1k so that treatment 1 is selected and the index of the selected
experimental treatment is s = 1.
Since separate control arms are assumed, stage 1 estimates are now uncorrelated
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In Section 6.6, independent increment statistics for the log HR were defined for stage
2. For the selected treatment in this case, the independent increment statistic is
given by θ̃21 (6.10). This statistic corrects for the correlation due to censoring and
is an unbiased but inefficient estimator for θ1. Hence, sufficient and complete statis-
tics are now sought in order to Rao-Blackwellise θ̃21 and derive an asymptotically
UMVCUE for θ1.
The joint density in (6.13) gives the distribution of stage 1 statistics and the stage
2 increment for treatment 1. Thus from this density, conditional on selection of
treatment 1, the joint density is




















where, IQs(θ) is the indicator function for Qs and P (θ) = Prob(IQs(θ) = 1).
To find sufficient and complete statistics for θ1, the result in expression (3.11) (Sec-













re-write density (6.14) as

















































θ̃21 and θ̃ = (θ̃
∗
1, θ̂12, ..., θ̂1K). Then f(θ̂11, ..., θ̂1K , θ̃21|Qs) can
be transformed into f(θ̂11, θ̃|Qs), and since the Jacobian of the transformation is 1,




























Hence, by the Factorisation Theorem 3.4.6 and Definition 3.4.8, from f(θ̂11, θ̃|Qs),
it follows that θ̃ is a complete, sufficient statistic for (θ1, ..., θK).






the densities required are, f(θ̃21, θ̃|Qs) and f(θ̃|Qs).
The density in the denominator is found by integrating density f(θ̂11, θ̃|Qs) with
respect to θ̂11 as follows. By the condition of selection, Qs, the range of θ̂11 is







































































































Using similar steps and following the result in Section 3.3.5, density (6.14) can be
re-expressed as







































θ̃21, by transformation of random variables (Section 3.1.1), the
density f(θ̃21, θ̃|Qs) can be derived from f(θ̂11, ..., θ̂1K , θ̃21|Qs) with Jacobian of the



























































































































θ̃21, the support of θ̃21 needed to Rao-Blackwellise θ̃21 is
given by A = σ21σ11 (θ̃
∗
1 − σ21σ11 θ̂12). Hence, using the result of the mean of a truncated
normal described in Section 3.3.2, the UMVCUE for θ1 accounting for selection of
the minimum log HR and correlation between stagewise statistics is































































The UMVCUE is asymptotically unbiased for the selected treatment. As separate
stage 1 estimates were assumed, this estimator is of a similar form to the Bowden
and Glimm estimator and the Kimani et al. estimator with no stopping for futility,
but with two main differences. Firstly, this estimator considers a selection rule
where the minimum log HR among all experimental treatments is selected at the
interim analysis, that is, the treatment with maximum efficacy. As can be seen in
93
the derivation, this difference in selection rule for estimation of a log HR, assuming
asymptotic normality, changes the limits of integration and thus the sign of the bias
correction from negative to positive.
Secondly, this estimator now adjusts for the correlation between stagewise estimates
due to censoring by defining independent increments for stage 2 data. This estimator
is therefore appropriate for time-to-event data and is an extension to the Bowden and
Glimm [2008] estimator where the differences are: directly estimating the treatment
difference although with separate control arms, selection of the minimum log HR
and accounting for correlation due to censoring.
6.8 Bias correction with a common control arm
Pairwise comparisons of each experimental treatment to a common control arm lead
to correlated stage 1 estimates at the interim analysis. The UMVCUE derived in the
previous section assumed separate control arms in order to maintain independence.
This section therefore replaces this assumption to account for correlated stage 1
statistics, as described by density (6.12).
A recent paper by Robertson et al. [2016] gives a general framework for calculat-
ing UMVCUE’s in the multivariate normal setting which explicitly accounts for
the correlation between stage 1 estimates. Their setting of interest is a two-stage
genome-wide association study where at the end of stage 1, estimates may be cor-
related. Using their general framework, the UMVCUE derived in the preceding
section is now adapted to account for the correlation within stage 1.
Recall the density for (θ̂11, θ̂12, ..., θ̂1K , θ̃21)
′ (6.12) derived in Section 6.6. Let Σ
denote the variance-covariance matrix for stage 1 statistics from density (6.12).
Since the stage 2 increment statistic, θ̃21, is unbiased for θ1, the UMVCUE for θ1 is
found by Rao-Blackwellisation of θ̃21, given sufficient and complete statistics. These
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are derived as follows.
Let θ̂ denote the vector of stage 1 estimates (θ̂11, ..., θ̂1K)
′ and θ denote the vector
of true log HRs (θ1, ..., θK)
′. Then, following expression (6.12) the joint density of θ̂
and the stage 2 independent increment, θ̃21, given by expression (6.12), conditional





















(θ̂ − θ)′Σ−1(θ̂ − θ)
}
.
Now in order to determine the sufficient and complete statistic for θ, the exponent





















θk − θ′Σ−1θ −
1
σ221
θ21 + ψ(θ̂, θ̃21)
]
,
where ψ(θ̂, θ̃21) = −θ̂′Σ−1θ̂− 1σ221 θ̃
2
21. Thus from the above density and as shown in
Appendix B, by Theorem 3.4.6 and Definition 3.4.8,




is sufficient and complete for θ where Σ1 = (σ1,1,1, ..., σ1,1,K)
′. Now by Rao-
Blackwellisation of the stage 2 increment, the UMVCUE is derived by E[θ̃21|θ̃∗, Qs].




From the definition of θ̃∗, we can write
θ̂ = θ̃∗ − Σ1
σ221
θ̃21. (6.22)


































where α1 and α2 are as defined in Section 6.7.
The density f(θ̃∗|Qs), also needed to derive the UMVCUE, is found by integrating
density f(θ̃21, θ̃
∗|Qs) (6.23) over the support of θ̃21. As we condition on selection of
the minimum log HR, the support of θ̃21 is found as follows.
The definition of Qs implies θ̂1k < θ̂1k+1 for k = 1, ...,K − 1. Thus from equation
(6.22)









=⇒ σ221(θ̃∗k − θ̃∗k+1) < θ̃21(σ1,1,k − σ1,1,k+1).













σ1,1,k−σ1,1,k+1 . However, if σ1,1,k = σ1,1,k+1 then there is no restriction
on the integral with respect to θ̃21. Putting all of these inequalities together gives


































, if σ1,1,k < σ1,1,k+1,
+∞, otherwise.
(6.25)







































Now using the result in equation (3.9) and following steps in Section 3.3.5, expres-
sion (6.26) is evaluated to give the asymptotic UMVCUE for time-to-event data.
This estimator corrects for selection of the minimum log HR and both within- and





























for i = 1, 2.
The form of this estimator is similar to the Robertson et al. [2016] estimator, which
corrects for selection of the maximum treatment mean and correlation between
stage 1 estimates. However, this new estimator corrects for treatment selection
in the opposite direction, that is, selection of the minimum log HR. Additionally,
this estimator corrects for both the correlation between stage 1 estimates and the
correlation between stage 1 and 2 estimates for the selected treatment.
97
The estimators derived in this chapter are summarised in Table 6.2.
Table 6.2: Summary of estimators for the selected log HR, θ1
Estimator Equation Description
θ̂1 -
Naive estimator from all accrued data at the final analysis
that ignores selection and both correlation within and
between stages.
θ̃21 (6.10) Stage 2 increment estimate for the selected treatment.
θ̃1a (6.19)
Asymptotic UMVCUE that accounts for selection and
correlation between stages but ignores correlation within
stage 1.
θ̃1b (6.27)
Asymptotic UMVCUE that accounts for selection and
both correlation between stages and within stage 1.
6.8.1 Bivariate asymptotic UMVCUE

































































6.9.1 Simulation set up
The properties of the stage 2 increment estimator, θ̃21, the naive estimator, θ̂1,
and the UMVCUE, θ̃1b, are now compared in a simulation study. Since we are
concerned with unbiased and efficient estimation, their bias and MSE are assessed
for the influence of the number of experimental treatment arms, treatment effect
sizes and selection times. As in the motivational simulation study (Section 6.3), up
to 6 experimental treatments are considered so that K ∈ {1, ..., 6} with selection
time defined by τ ∈ {0.1, ..., 0.9}. Various scenarios for different effect sizes are
considered: scenario (a) assumes all experimental treatments are equally ineffective,
where log HRs θk = 0 (k = 1, ...,K); (b) assumes all treatments are equally effective,
where θk = −0.22 (k = 1, ...,K); and (c) assumes one uniquely superior treatment,
where θ1 = −0.22 and θk = 0 (k = 2, ...,K). Additionally, unequal effect sizes are
assumed for all treatment arms to assess a range of effect sizes from small to large
log HRs. Here, log HRs θk = −0.05k (k = 1, ...,K), which correspond to HRs from
0.78 to 0.95.
This simulation study is set up to resemble a seamless phase II/III clinical trial
with patients randomised by blocked randomisation with block size 2(K + 1). This
means that two patients are allocated to each experimental treatment and control
arm within each block. Randomisation times are simulated from 0 to 6 months from
a uniform distribution for a total of n = 1500 patients per group. Event times Ej are
simulated for each patient j = 1, ..., n from a Weibull distribution using the R pack-
age by Stasinopoulos et al. [2006], with shape parameter γ = 1.5 for all arms and a
range of rate parameters λc ∈ {0.15, 0.25} and λk ∈ {0.03, 0.1, 0.12, 0.15} for the con-
trol arm c and experimental treatment arms k. Random censoring times Cj are simu-
lated for each patient j = 1, ..., n for each arm from an exponential distribution with
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rate 0.001. A patients survival time is thus calculated as min{Ej , Cj}. The survival
times assumed here correspond to true log HRs θk ∈ {−1.61,−0.92,−0.51,−0.22, 0}.
The main assumption here is that the distribution of event times is stochastically
independent of the censoring time distribution.
As discussed, for time-to-event data, the information fraction depends on the number
of events. Therefore, the total number of events at the final analysis is set to
D = 900, such that the total number of events at the interim analysis is d = τD.
Additionally, the length of follow-up for patients recruited in stage 1 with censored
events at the interim analysis is limited to Tfollow, as described in Section 6.4. Thus,
the additional number of events from these patients is defined as Dfollow = d +
0.1D.
In each simulated trial, at the end of stage 1, an interim analysis is conducted where
log HRs, θ̂1k, are estimated based on the log-rank score statistic and variance as
described in Section 6.6 and equations (6.1) and (6.2). The observed effect sizes
for each treatment are ranked in order of decreasing magnitude and the treatment
associated with the smallest log HR is selected to take forward into stage 2. At the
end of stage 2, after a total of 900 events, including delayed events followed-up until
Tfollow, a final analysis is conducted where the estimators of interest given in Table
6.2 are computed.
A naive estimator, θ̂1, is computed as described in Section 6.3. This estimator does
not account for selection or correlation, and is obtained at the final analysis based on
all accrued data for the selected treatment and control arm. The stage 2 increment,
θ̃21, is computed as described by equation (6.10). This increment estimate is the
difference between the estimate from all trial data, where delayed events from stage
1, which occur after Tfollow are censored at Tfollow, and the estimate computed at the
interim analysis for the selected treatment. The asymptotic UMVCUE is computed
using expressions (6.27), (6.24), (6.25) and (6.21). In order to compute the sufficient
100
statistics θ̃∗, the covariance of any two ordered stage 1 statistics is obtained as
described by equation (6.11).
The average selection bias and RMSE are calculated from 10,000 simulated trials for
each value of K and 9 values of τ in the interval (0.1,0.9). For each trial, selection
bias of each estimator for the selected treatment is calculated as the mean of the
differences in the estimated log HR and the true log HR. The MSE is calculated
as the mean of the squared differences between the estimator and the true log HR.
Recall, since θk < 0 (k = 1, ...,K) implies superiority of treatment k, a negative bias
implies a positively biased estimator, that is, the estimator overestimates the true
treatment effect.
6.9.2 Simulation results
Figures 6.4 shows the bias (top plots) and RMSE (bottom plots) of the stage 2
increment as a function of selection time for scenarios (a)-(c). The bias and RMSE
for asymptotic UMVCUE are given in Figure 6.5. For the case of equally ineffective
treatments, that is, when θk = 0 (k = 1, ...,K), it can be seen that the stage 2 in-
crement and the new UMVCUE are asymptotically unbiased for all selection times
and for any number of experimental treatment arms, up to six. The stage 2 incre-
ment has a larger RMSE compared to the UMVCUE. Specifically, when selection
is made later in the trial, it can be seen that the RMSE of the stage 2 increment
increases steeply with selection time. This reduction in efficiency is expected since
this estimator is the difference between the final estimate and the interim estimate.
The UMVCUE, on the other hand, has a much improved RMSE for all values of
K, with a small increase observed for late selection times of τ > 0.8. Hence, the
UMVCUE has better properties than the stage 2 increment estimator.
In comparison to the simulation study of the naive estimator (Figure 6.2), the new
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UMVCUE corrects for the overestimation of treatment effects in the naive estimator
for all selection times and any number of experimental treatment arms. Specifically,
Figure 6.6 shows a comparison of all estimators for the case of 2, 4 and 6 experimental
treatment arms. In terms of RMSE, the UMVCUE has a larger RMSE compared
to the naive estimator. This was also shown for the normal case by Kimani et al.
[2013], where they observed a larger RMSE for their UMCUE compared to the naive
estimator for all selection times. As can be seen the difference in RMSE’s decreases
with the number of experimental treatment arms (Figure 6.6 (bottom)).
In Section 6.3, it was shown that the naive estimator is positively biased in all
cases with bias increasing with the number of experimental treatment arms. In
particular, for the case of equally effective treatments (scenario (b)), overestimation
of up to -0.04 was observed for the naive estimator. The new UMVCUE shows a
considerable improvement in this bias for all selection times compared to the naive
estimator (Figure 6.5(b)). For selection times of τ < 0.8, bias appears to improve
with the number of experimental treatment arms K. However, for late selection
times τ > 0.8, the UMVCUE slightly underestimates the true effect for trials with
a small number of treatment comparisons (K ≤ 3) and slightly overestimates for
trials with a large number of treatment comparisons (K ≥ 6) (Figure 6.7). This
implies that the UMVCUE provides a more conservative estimate of the selected
treatment effect in cases with a small number of treatment comparisons for late
selection times. However, this is still a considerable improvement in bias over the
naive estimator and, as discussed in Section 6.3, this is due to the inherent bias of
the asymptotic normality assumption.
In terms of RMSE, as was observed for the case of equally ineffective treatments, the
UMVCUE has a larger RMSE, when all treatments are equally effective, compared
to the naive estimator for all values of τ and K, with a gradual increase observed
with selection time up to τ = 0.8.
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K=2 K=3 K=4 K=5 K=6
Figure 6.4: Bias (top row) and RMSE (bottom row) of the stage 2 increment estimator θ̃21 for K ∈ {2, ..., 6} treatment groups
and selection times τ ∈ {0.1, ..., 0.9} from 10,000 simulations. Each column represents a different combination of effect sizes: (a)
θk = 0 ∀k ∈ {1, ...,K}, (b) θk = −0.22 ∀k ∈ {1, ...,K}, and (c) θ1 = −0.22 and θk = 0 ∀k ∈ {2, ...,K}.
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K=2 K=3 K=4 K=5 K=6
Figure 6.5: Bias (top row) and RMSE (bottom row) of the asymptotic UMVCUE for K ∈ {2, ..., 6} treatment groups and
selection times τ ∈ {0.1, ..., 0.9} from 10,000 simulations. Each column represents a different combination of effect sizes: (a)
θk = 0 ∀k ∈ {1, ...,K}, (b) θk = −0.22 ∀k ∈ {1, ...,K}, and (c) θ1 = −0.22 and θk = 0 ∀k ∈ {2, ...,K}.
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Figure 6.6: Bias (top row) and RMSE (bottom row) of the naive estimator, stage 2 increment estimator, and asymptotic UMVCUE
for a different number of treatment groups K and selection times τ ∈ {0.1, ..., 0.9}, from 10,000 simulations. For each experimental
treatment arm k, log HRs θk = 0 ∀k ∈ {1, ...,K}.
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Figure 6.7: Bias (top row) and RMSE (bottom row) of the naive estimator, stage 2 increment estimator, and asymptotic UMVCUE
for a different number of treatment groups K and selection times τ ∈ {0.1, ..., 0.9}, from 10,000 simulations. For each experimental
treatment arm k, log HRs θk = −0.22 ∀k ∈ {1, ...,K}.
106
A similar result is observed for the case of one superior treatment, as can be seen
in Figure 6.5(c). However, the magnitude of bias is overall smaller than the case of
equally effective treatments with θk = 0.8 (k = 1, ...,K). This is expected since we
have seen previously that bias reduces as the difference in the selected treatment
effect and second best treatment effect increases.
For all scenarios, the UMVCUE RMSE appears to increase steeply for late selection
times τ > 0.8. Additionally, for the case of one superior treatment, the RMSE
increases with the number of experimental treatments for selection times τ > 0.8.
This is similarly observed for the stage 2 increment, with a steeper increase across
selection times. This is partly due to the inherent bias from the normality assump-
tion, but also due to the correlation between stage 1 and 2 data, as later selection
times correspond to a larger information fraction which means a greater proportion
of events from patients recruited in stage 1 are included in the final analysis.
Despite the new UMVCUE having a slightly larger RMSE compared with the naive
estimator, these simulations have shown a substantial improvement in bias over
the naive estimator for all selection times. These results therefore show that the
UMVCUE has considerably better properties than the naive estimator, since it cor-
rects for the substantial bias that arises from both treatment selection and correla-
tion due to censored observations. However, as the UMVCUE is only asymptotically
unbiased, where the normality approximation of the log-rank score statistics are only
appropriate for small to moderate treatment effects, it is important to consider the
treatment effect size in the bias and RMSE trade-off.
Therefore, we now assess the influence of the effect size on bias and RMSE. We
first assume equal log HRs for all experimental treatment arms in the range -1.61
to 0. Log HRs θk ≤ −0.9 are considered large effect sizes, while −0.9 < θk < 0 are
considered moderate to small effect sizes. Table 6.3 shows the bias and RMSE of
the naive estimator, θ̂1, the stage 2 increment estimate, θ̃21, and the UMVCUE, θ̃1b,
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for selection times τ = (0.3, 0.5, 0.8) for the case of K = 4 experimental treatment
arms. For large effect sizes, it can be seen that all estimators underestimate the true
treatment effect, with the UMVCUE performing the worst. Additionally, Figure
6.8(a) indicates the UMVCUE bias increases with effect size and selection time,
where a bias of up to 0.3 is observed for a large log HR (θk = −1.61). However,
in a comparison of Figures 6.8(a)-(c), bias appears to reduce as the number of
experimental treatments increase. Therefore, this indicates that for large HRs the
UMVCUE does not correct for the bias due to treatment selection, as we have
previously observed that selection bias in the naive estimator is influenced by the
number of experimental treatment arms. Furthermore, a considerable difference in
RMSE for θk = −1.61 and θk > −1.61 can be seen in all cases of K. These results,
therefore, highlight that the asymptotic approximation of the log HR does not hold
for large treatment effects. Hence, due to both the asymptotic assumptions as well
as bias due to selection of large log HRs, the UMVCUE is only appropriate for small
to moderate effect sizes.
Now to assess the effect of varying log HRs, we assume true effect sizes θk = −0.05k
(k = 1, ...,K), which correspond to HRs from 0.78 to 0.95. Figure 6.9 shows the
bias (top row) and RMSE (bottom row) of the naive estimator, θ̂1, the stage 2
increment estimate, θ̃21, and the UMVCUE, θ̃1b, for selection times τ ∈ {0.1, ..., 0.9}
and K = {1, ..., 6} experimental treatment arms. The UMVCUE corrects for the
overestimation of treatment effects in the naive estimator, as was similarly observed
for the normal case of unequal means in Chapter 5. As can be seen, the UMVCUE is
asymptotically unbiased for all selection times for K ≤ 4. However, for late selection
times τ > 0.8, all estimators indicate a small increase in bias for increasing number
of experimental treatments. In terms of RMSE, the stage 2 increment has a larger
RMSE compared to the naive estimator and UMVCUE, as expected. In particular,
the RMSE increases more steeply as both selection time increases and the number
of experimental treatments reduces. In contrast, the UMVCUE has an improved
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Table 6.3: Mean bias and RMSE from 10,000 simulations of the naive estimator (θ̂1),
the stage 2 increment (θ̃21), and the UMVCUE (θ̃1b) for the case of two experimental
treatment arms at selection times τ = {0.3, 0.5, 0.8}. Log HRs θk (k = 1, ..., 4) are
assumed to be equal for each scenario.
True effect size
θk: 0 -0.22 -0.51 -0.92 -1.61
τ Estimator HR: 1 0.8 0.6 0.4 0.2
Bias 0.3 θ̂1 -0.0145 -0.0113 -0.0047 0.0180 0.1345
θ̃21 0.0004 0.0056 0.0138 0.0374 0.1460
θ̃1b 0.0006 0.0045 0.0118 0.0350 0.1493
0.5 θ̂1 -0.0168 -0.0154 -0.0087 0.0147 0.1372
θ̃21 0.0034 0.0066 0.0168 0.0422 0.1610
θ̃1b 0.0032 0.0054 0.0132 0.0375 0.1603
0.8 θ̂1 -0.0224 -0.0180 -0.0088 0.0104 0.1220
θ̃21 0.0043 0.0127 0.0279 0.0528 0.1739
θ̃1b 0.0041 0.0095 0.0210 0.0428 0.1608
RMSE 0.3 θ̂1 0.0641 0.0633 0.0625 0.0635 0.1463
θ̃21 0.0665 0.0668 0.0693 0.0771 0.1602
θ̃1b 0.0649 0.0654 0.0670 0.0743 0.1618
0.5 θ̂1 0.0654 0.0642 0.0623 0.0625 0.1481
θ̃21 0.0716 0.0714 0.0744 0.0843 0.1760
θ̃1b 0.0683 0.0680 0.0696 0.0783 0.1731
0.8 θ̂1 0.0669 0.0649 0.0616 0.0616 0.1345
θ̃21 0.0802 0.0817 0.0869 0.1007 0.1957
θ̃1b 0.0725 0.0737 0.0770 0.0875 0.1788
RMSE, with only a gradual increase observed across selection times. However, the
RMSE is overall larger for all values of K compared to the naive estimator, as was
observed in previous scenarios and for the normal case.
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HR=1 HR=0.8 HR=0.6 HR=0.4 HR=0.2
Figure 6.8: Bias (top row) and RMSE (bottom row) of the asymptotic UMVCUE for a range of effect sizes from 10,000 simulations.
A range of HRs (0.2,1) are assumed equal for K treatment arms and selection times τ ∈ {0.1, ..., 0.9}.
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K=2 K=3 K=4 K=5 K=6
Figure 6.9: Bias (top row) and RMSE (bottom row) of the naive estimator, stage 2 increment estimator, and asymptotic
UMVCUE for unequal effect sizes for each treatment arm from 10,000 simulations. For each experimental treatment arm k, log
HRs θk = −0.05k ∀k ∈ {1, ...,K}.
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6.10 Conclusion
This chapter addressed the importance and need for unbiased and efficient estima-
tors for time-to-event data in seamless phase II/III clinical trials. The problem
of selection bias arises when data are used for both selection of the most effective
treatment at the interim stage, as well as estimation of the treatment effect at the
final analysis. Methods of estimation that account for this problem use the tech-
nique of Rao-Blackwellisation of the unbiased but inefficient stage 2 data. However,
these methods only exist for normally distributed data and are thus not appropriate
for censored survival data. Therefore, by extension of these methods, this chapter
developed two asymptotically unbiased estimators that correct for selection bias as
well as correlation of stagewise estimates due to censored observations at the interim
analysis.
Independent increment statistics were introduced in order to decorrelate stagewise
statistics and thus derive the joint asymptotic distribution of stage 1 and stage 2
log HRs. The first estimator assumed separate control arms in order to decorrelate
stage 1 estimates. An asymptotic unbiased estimator correcting for selection bias
and correlation between stages was derived by extension of the ideas from Bowden
and Glimm [2008], Di Scala and Glimm [2011] and Kimani et al. [2013]. However, the
main limitation of this estimator is that it assumes a separate control group for each
experimental treatment group. In practice, this may not be a realistic assumption
as investigators and regulators are generally interested in saving resources, such as
costs and the number of patients recruited in a trial.
Therefore, since a common control arm is generally considered in practice, the sec-
ond estimator derived in this chapter replaces this assumption to include a common
control arm for all experimental treatment arms. This however leads to correlated
stage 1 estimates due to the common control arm. Thus, extending the previous es-
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timator with the methods given by Robertson et al. [2016] for a multivariate normal
setting, the second UMVCUE developed corrects for both the correlation between
stage 1 estimates as well as the correlation between stages, while also adjusting for
treatment selection bias for time-to-event data.
Properties of the UMVCUE with a common control arm were compared to the naive
estimator and stage 2 increment estimator in a simulation study for various trial
scenarios. Under the null, the UMVCUE was found to be asymptotically unbiased
for any selection time and any number of experimental treatments. Furthermore,
a substantial improvement in bias was observed in the UMVCUE compared to the
naive estimator for small to moderate effect sizes, with bias improving with the
number of experimental treatment arms. However, for large effect sizes, such as a
HR of 0.2, results highlighted that the asymptotic assumptions of the log HR fail to
hold. Therefore, the UMVCUE has favourable properties over the naive estimator






In targeted therapy trials, a biomarker is used to identify a subset of patients with
certain molecular or gene expressions. It is thought that this subgroup or subpopu-
lation may respond better to treatment than the full population [Buyse et al., 2011].
Figure 7.1 illustrates the population in a given trial, where the full population, F , is
made up of the subpopulation of interest, defined as the biomarker-positive group,
S, and its complement Sc, defined as the biomarker-negative group. This setting
is common in targeted therapy trials and is therefore the setting assumed in this
chapter.
Statistical analysis of such data encounters multiplicity issues as treatment efficacy
is assessed in the biomarker-positive subgroup as well as the full population in order
to identify the population that benefits from the new intervention. As discussed





Figure 7.1: Population diagram. The full population is denoted by F , and the
biomarker-positive and biomarker-negative subpopulations are denoted by S and
Sc, respectively.
confirming phases of drug development may be more efficient in addressing multiple
clinical questions within one trial. In the setting of subpopulation selection, two-
stage designs allow both selection of the subpopulation to be made in an independent
learning phase, as well as testing of treatment efficacy in a confirmatory phase III
setting. This is an attractive design where both phases are combined into a single
two-stage trial as illustrated in Figure 7.2.
In stage 1, randomisation to the control arm or experimental treatment arm is
stratified by the prespecified biomarker subpopulations S and Sc to ensure an equal
number of patients are assigned to each arm within each subpopulation. At the
interim analysis, the decision of whether to continue the trial to stage 2 with either
the biomarker-positive subpopulation, S, or the full population, F , is based on a
predefined selection criterion. If the treatment is deemed sufficiently effective in the
biomarker-positive subpopulation, then trial continues with S only. On the other
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Figure 7.2: Two stage trial schema with subpopulation selection
hand, if the treatment effect in the subpopulation is not sufficiently better than the
effect in the full population, then the trial continues with the full population. This
is described in more detail in Section 7.3.
Although this design is beneficial in combining two phases of drug development into
a single trial, statistical issues arise with treatment effect estimation and multiple
hypothesis testing. A chance selection of the most promising population may occur
at the interim analysis which may lead to bias in the naive estimate from stage 1
data. Hence, at the end of the trial, the final effect estimate may be overestimated
and thus biased as stage 1 data are used for both population selection as well as esti-
mation of treatment efficacy. Several papers, including Friede et al. [2012], Hommel
[2001] and Glimm and Di Scala [2015], propose methods that address multiplicity
which arises in hypothesis testing for normally distributed data in this setting. For
time-to-event data, papers including Brannath et al. [2009], Jenkins et al. [2011] and
Mehta et al. [2014] address the issues of multiplicity for various trial settings with
subpopulation selection at the interim. Specifically, Jenkins et al. [2011] propose
using prespecified weights in order to utilise all trial data and thus ensure inde-
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pendence of stagewise statistics for time-to-event data. Additionally, Glimm and
Di Scala [2015] suggest their method holds under the assumptions of asymptotic
normality of the log-rank test statistic or the Cox regression coefficient of the treat-
ment effect. All of these methods, however, focus on statistical testing of the null
hypothesis rather than estimation of the treatment effect.
In terms of point estimation, for normally distributed outcomes, Kimani et al. [2015]
propose conditionally unbiased estimators correcting for subpopulation selection
bias in two-stage trials. They derive UMVCUEs for treatment means of the selected
population, S or F . For time-to-event outcomes, point estimators that account
for subpopulation selection have not been developed. Therefore, in this chapter
we combine the methods from Kimani et al. with those developed in the previous
chapter in order to derive asymptotically conditionally unbiased estimators. We
assume the setting of subpopulation selection in Kimani et al. [2015], but for time-
to-event data.
7.1.1 Sources of bias
In two-stage two-arm survival trials, as mentioned before, bias may be introduced in
the naive estimator as data from all patients recruited up until the interim analysis
time are used for both subpopulation selection as well as estimation of the treatment
effect at the final analysis.
In addition, censoring at the interim analysis leads to correlated stagewise test
statistics due to the continued follow-up in stage 2 of patients recruited in stage 1.
As described in the previous chapter, such data are referred to as delayed events.
Thus, bias may depend on the additional follow-up of stage 1 patients with delayed
events. In order to ensure the information in stage 2 does not depend on data
observed from patients recruited in stage 1, the length of additional follow-up time
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for such delayed events should be prefixed and unrelated to the selection rule, as
discussed in Section 6.4.
7.2 Notation
Consider a two-stage two-arm trial with one experimental treatment compared to
a control in two subpopulations denoted by k = {S, Sc}. Let pk denote the known
sample prevalence of subpopulation k from the full population F . Suppose ni pa-
tients are recruited in each stage i (i = 1, 2) and let nik = pk ·ni denote the number
of patients in subpopulation k in stage i, where recruitment is constrained in each




n2S if S is selected
n2S + n2Sc if F is selected.
Key notation for this chapter is summarised in Table 7.1.
7.2.1 Estimating the log HRs
As interest is in the survival distributions within two subpopulations S and Sc,
separate log HRs are estimated for the treatment effect within each subgroup. Let
θk denote the true log HR for the experimental treatment in subpopulation k (k =
S, Sc) and θ̂1k denote the estimated log HR for subpopulation k in stage 1. If
S is selected, let θ̂2S denote the estimated log HR at the final analysis, and if F
is selected, let θ̂F2k denote the estimated log HR for subpopulation k at the final
analysis.
As before, stagewise log HRs are computed based on the log-rank score statistic















Table 7.1: Key notation
Selected population Subpopulation Stage 1 Stage 2 Stages 1 and 2
Naive estimator Sufficient statistic Unbiased estimator
S S θ̂1S ∼ N(θS , σ21S) θ̃2S ∼ N(θS , σ22S) θ̂S θ̃∗S θ̃S
Sc θ̂1Sc ∼ N(θSc , σ21Sc) - - - -














(i = 1, 2) are as defined by equations (6.1) and (6.2). Hence, θ̂1k is asymptotically






As discussed in Section 6.6, to ensure independence between stagewise test statistics
for time-to-event outcomes, independent increments are utilised with a prespecified
additional follow-up time for stage 1 delayed events. If S is selected, as the stage











On the other hand, if F is selected, then independent increments are defined for
each subpopulation k (k = S, Sc) by
θ̃F2k =
SF2k − S1k
V F2k − V1k
, (7.2)






7.3 Subpopulation selection rule
A treatment is deemed most efficacious if it is one with the smallest observed log
HR. In terms of subpopulation selection, at the interim analysis the trial continues
with subpopulation S if the experimental treatment is observed to be sufficiently
more effective in S than in F . Subpopulation S is selected if θ̂1S < θ̂1Sc − c, where
c is chosen depending on the subpopulation prevalence. Let Q denote the condition
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of selection such that
Q =

θ̂1S < θ̂1Sc − c if S is selected
θ̂1S ≥ θ̂1Sc − c if F is selected.
(7.3)
The selection margin c may be thought of as a penalty for small subpopulations,
where the smaller the subpopulation, the less likely it is to be selected. For example,
c may be defined by c = bpS , since dividing by the prevalence ensures that S is only
selected if a strong effect exists. The numerator b may be derived, for example, using
an economic gain function defined by the number of QUALY gains for selecting the
subpopulation S [Ondra et al., 2016].
7.4 Case where S is selected
First consider the case where the experimental treatment is sufficiently more effective
in subpopulation S compared to the full population F , such that the trial continues
to the second stage with S.
7.4.1 Naive estimator for θS
As defined in Section 7.2.1, at the interim and final analysis, estimators θ̂1S and θ̂2S
are obtained based on the log-rank score statistics from all data accrued up until each




Using independent increments to decorrelate stagewise estimates, we can derive the
joint distribution of stage 1 statistics and the stage 2 increment statistic for the
selected subpopulation. Recall stage 1 estimates are uncorrelated since separate
subgroups are considered. Therefore, following Section 6.6 the joint asymptotic
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A naive estimator for the treatment effect at the final analysis can be defined as the
weighted sum of the stage 1 log HR and the stage 2 increment statistic, weighted
by the information in each stage.




. Thus, in the case where S is selected, the naive estimator is defined
by
θ̂S = τS θ̂1S + (1− τS)θ̃2S . (7.5)
At the final analysis, the naive estimator overestimates the true treatment effect
when selection is made with respect to subpopulations. Hence, the resulting esti-
mator, θ̂S , is positively biased.
7.4.2 An asymptotically UMVCUE for θS
This section addresses the issue of bias due to subpopulation selection by deriving
a UMVCUE, which corrects for selection bias based on the asymptotic normality
assumption of the log-rank score statistic. This estimator is based on Kimani et al.
[2015]. Since the independent increments property is utilised, this estimator also
accounts for the correlation which arises due to censored events at the interim anal-
ysis. Furthermore, as was discussed in the previous chapter, this assumption of an
independent covariance structure only holds as long as test statistics are unchanged.
122
Therefore in order to ensure independence is satisfied, the maximum follow-up time
for censored stage 1 events is limited and prespecified, as described in Section 6.4.
Additionally, due to the asymptotic assumptions, we note this estimator is only
asymptotically unbiased for large samples and small effect sizes.
Recall from equation (7.3) if the subpopulation S is selected then Q = θ̂1S < θ̂1Sc−c.
Thus, conditional on selection and following density (7.4), the joint density of the
stage 1 log HRs and the stage 2 increment for the selected subpopulation is
























where I[Q(θ)] is the indicator function for Q and P (θ) = Prob(I[Q(θ)] = 1).
Since the increment θ̃2S is unbiased for θS , the UMVCUE is derived using the
method of Rao-Blackwellisation (Theorem 3.5.3). Therefore, the required complete,
sufficient statistics for θS are now derived as follows.
Following the result in expression (3.11), the above joint density is re-expressed
as
























































θ̃2S , then by
transformation of random variables, density f(θ̂1S , θ̂1Sc , θ̃2S |Q) can be transformed
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to f(θ̂1S , θ̂1Sc , θ̃
∗
S |Q) with the Jacobian being
σ2S
σ1S
, to give the density



























Hence, by the Factorisation Theorem 3.4.6, from the above density it follows that
(θ̃∗S , θ̂1Sc) is minimal sufficient and thus a complete and sufficient statistic for θS .
Now, to derive the UMVCUE we need to find the expression for E[θ̃2S |θ̂1Sc , θ̃∗S , Q].
Since E[θ̃2S |θ̂1Sc , θ̃∗S , Q] =
∫
θ̃2Sf(θ̃2S |θ̂1Sc , θ̃∗S , Q), by standard theory of conditional
probabilities we seek the densities f(θ̃2S , θ̂1Sc , θ̃
∗
S |Q) and f(θ̂1Sc , θ̃∗S |Q). The latter
density is found by solving the integral
∫
f(θ̂1S , θ̂1Sc , θ̃
∗
S |Q)dθ̂1S . From the condition





































































Now to find the density f(θ̃2S , θ̂1Sc , θ̃
∗
S |Q), by following the steps described in section
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3.3.5, density (7.6) is re-expressed as







































Thus, by transformation of random variables (Section 3.1.1) density f(θ̂1S , θ̂1Sc , θ̃2S |Q)
is transformed to f(θ̃2S , θ̂1Sc , θ̃
∗





























Hence, the conditional density of θ̃2S given complete, sufficient statistics required to
derive the UMVCUE is
f(θ̃2S |θ̂1Sc , θ̃∗S , Q) =
f(θ̃2S , θ̂1Sc , θ̃
∗
S |Q)





















. Hence, using the result of a truncated normal density
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(expression (3.9)), the UMVCUE, θ̃S , is found by
E[θ̃2S |θ̂1Sc , θ̃∗S , Q] =
∫ ∞
L


































































Hence, the UMVCUE when subpopulation S is selected is








7.5 Case where F is selected
If at the interim analysis, the treatment in the biomarker-positive subpopulation is
not sufficiently more effective than the full population, then the trial continues with
the full population. Hence, as per the selection rule in Section 7.3 the condition of
selection is now defined by Q = θ̂1S ≥ θ̂1Sc − c. In this case, follow-up in stage 2
continues in both S and Sc with new patients randomised to the experiential treat-
ment and control arms in both subgroups. Hence, an estimate for the subpopulation
complement, Sc, is now also observed, where interest at the final analysis is in the
overall treatment effect in the full population, θF . However, if the full population is
selected, θS and θSc both exist which means the odds are proportional for both S
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and Sc and therefore the proportionality assumption cannot hold for F unless the
following two conditions hold: i) there is no difference in the hazard rate of S and
Sc and ii) the hazard ratio is the same in S and Sc when F is selected.
7.5.1 Naive estimators
A naive estimator for θF is derived as the pooled estimate of each subpopulation
effect weighted by the prevalence. Conditional on selection, naive estimators at the




). Recall from equation (7.2), θ̃F2S ∼ N(θS , σ22SF ) and θ̃
F
2Sc ∼ N(θSc , σ22ScF )
are the stage 2 independent increment estimates for subgroup S and Sc, which
account for the correlation between stage 1 and stage 2 estimates. As the trial
continues with the full population, the information fraction for the subpopulation
k is τFk =
V1k
V F2k
(k = S, Sc). Thus, for the biomarker-positive subgroup, a naive
estimator is defined by
θ̂FS = τ
F
S θ̂1S + (1− τFS )θ̃F2S
and for the biomarker-negative subgroup, a naive estimator is defined by
θ̂FSc = τ
F
Sc θ̂1Sc + (1− τFSc)θ̃F2Sc .
Hence, the naive estimator when the full population is selected is given by
θ̂F = pS θ̂
F
S + pSc θ̂
F
Sc . (7.11)
Since pS and pSc change over time based on the hazard rate, the effect in the full
population is calculated at time zero, that is, at the start of trial.
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7.5.2 Asymptotically unbiased estimators
When the full population is selected, treatment efficacy is estimated for both the
subpopulation, S, and its complement, Sc. Following equation (7.3), conditional on
Q, stage 2 increment estimates θ̃F2S and θ̃
F
2Sc are unbiased for θS and θSc , respectively.
Thus, by the technique of Rao-Blackwellisation of these estimates, derivation of the
UMVCUEs for θS and θSc follow the same steps as described in Section 7.4.2, where


















































θ̃F2Sc , which are suf-
ficient and complete for θS and θSc . Hence, by Rao-Blackwellisation, the UMVCUE
for θS when F is selected is
θ̃FS = E[θ̃
F


















θ̂FS − (θ̂1Sc − c)
}
.
Similarly for θSc , conditional on Q, and sufficient and complete statistics (θ̂1S , θ̃
∗
Sc),
the UMVCUE for θSc is given by
θ̃FSc = E[θ̃
F

















θ̂1S − c− θ̂FSc
}
.
Therefore, an unbiased estimator for θF is the weighted sum of the UMVCUEs
obtained for each subpopulation, weighted by the subpopulation prevalences at time
zero, that is,
θ̃F = pS θ̃
F




7.6.1 Simulation set up
The properties of the estimators derived in this chapter are now compared in a
simulation study. We envisage a two-stage trial with one experimental treatment
compared to a control arm, with randomisation stratified by subpopulation status.
We assess the influence of the treatment effect size, the subpopulation prevalence
and the selection time on bias and RMSE of the naive and unbiased estimators. The
simulation study is set up as described in Section 6.9.1 with survival times simulated
from a Weibull distribution corresponding to a range of true log HRs from -0.92 to
0. Since the simulation study in the previous chapter found selection bias to be
greatest for equal effect sizes, we assume a common treatment effect in S and Sc,
that is, θS = θSc . A range of subpopulation prevalences pS ∈ {0.4, 0.5, 0.7} are
considered for selection times τS ∈ {0.3, 0.5, 0.7}, which is the information fraction
for subpopulation S.
In each simulated study, at the interim analysis estimates θ̂1k are obtained for each
subgroup k (k = S, Sc) based on a stratified log HR, as described in equation (4.11).
The trial continues with the either the subpopulation S or the full population F .
We assume the selection margin c = bpS is equal to 0, which is considered the worst
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case scenario. Thus, if θ̂1S < θ̂1Sc subpopulation S is selected, otherwise F is
selected.
The total number of events at the final analysis is set to D = 1500 with an interim
analysis conducted after d events, where d = τSD. Additionally, as in the previous
chapter, the number of delayed events is defined as Dfollow = d+ 0.1D. In the case
where S is selected, the final analysis is conducted after D events have been observed
in subpopulation S. In the case where F is selected, the final analysis is conducted
after D events have been observed over both subgroups S and Sc.
At the final analysis, estimates are computed as described by equations (7.5) and
(7.10), if S is selected, and equations (7.11) and (7.15), if F is selected.
7.6.2 Simulation results
In the case where S is selected, Table 7.2 presents the average bias and RMSE
from 10,000 simulated studies of the naive estimator θ̂S and the UMVCUE θ̃S .
It can be seen that θ̃S is unbiased for small effect sizes, that is, a HR of 0.8 or
greater. Bias improves as the subpopulation prevalence increases, however there is
a slight increase in bias with selection time τS . This is expected as we observed
in the previous chapter, bias increases as the interim analysis is performed later
in the trial. Additionally, for θS ≥ −0.22, we find the UMVCUE corrects for the
overestimation of the treatment effect in the naive estimator; as can be seen there
is a small positive bias which increases with both subpopulation prevalence and
selection time.
For large effect sizes, bias in the naive estimator is found to be equivalent to bias
in the new estimator; for example, in the case where pS = 0.7, for θS = −0.92, θ̂S
and θ̃S both overestimate the true effect size by 0.0293. Additionally, comparable
to the simulation results in Chapter 6 for treatment selection, the RMSE of the
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UMVCUE is larger than that of the naive estimator. These results indicate that
the asymptotic normality approximation of these estimators are not appropriate
for such large effect sizes. This is because the normality approximation is only
reasonable under small effect sizes when groups have equal sample sizes. Therefore,
as the effect size increases the normality approximation fails due to the tailor series
approximation around the log HR of zero. The further we move away from this the
worse the approximation is.
If F is selected, Table 7.3 gives the average bias and RMSE from 10,000 simulations
of θ̂F and θ̃F . Similar results are observed to the case when S is selected for large
effect sizes. It can be seen the properties of the naive estimator and UMVCUE
are comparable. However, the UMVCUE is only asymptotically unbiased under the
null, that is, if θS = 0. The underestimation observed in both estimators for θS 6= 0
is due to the non-constant hazard ratio in the full population. As discussed in
Section 7.5, when F is selected, proportional hazards in each subpopulation means
the proportionality assumption no longer holds in the full population.
7.7 Conclusion
This chapter aimed to address the issues with estimation in two-stage confirmatory
trials with subpopulation selection. The problem of correlated stagewise estimates
due to censoring at the interim analysis was addressed by utilising independent
increments. To correct for the bias due to selection, by extension of the methods by
Kimani et al. [2015], UMVCUEs were derived by Rao-Blackwellisation of the stage
2 increment estimates, conditional on selection. The subpopulation selection rule
considered a margin of benefit, where the subpopulation S is only selected if it is
sufficiently more effective than the full population by some margin c.
If the experimental treatment is not sufficiently more effective in the biomarker-
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Table 7.2: Mean bias and RMSE from 10,000 simulations of the naive estimator (θ̂S) and the UMVCUE (θ̃S) for the case where S is
selected. A range of log HRs θS are considered for subpopulation prevalence pS ∈ {0.4, 0.5, 0.7}, selection times τS ∈ {0.3, 0.5, 0.7}
and selection margin c = 0.
Bias RMSE
θS : 0 -0.22 -0.51 -0.92 0 -0.22 -0.51 -0.92
pS τS Estimator HR: 1 0.8 0.6 0.4 1 0.8 0.6 0.4
0.4 0.3 θ̂S -0.0077 -0.0073 -0.0164 -0.0322 0.0473 0.0463 0.0519 0.0613
θ̃S 0.0051 -0.0001 -0.0141 -0.0321 0.0511 0.0485 0.0524 0.0613
0.5 θ̂S -0.0123 -0.0029 -0.0201 -0.0445 0.0466 0.0504 0.0530 0.0684
θ̃S 0.0034 0.0080 -0.0187 -0.0445 0.0521 0.0577 0.0536 0.0684
0.7 θ̂S -0.0150 -0.0076 -0.0244 -0.0428 0.0492 0.0538 0.0567 0.0686
θ̃S 0.0079 0.0058 -0.0238 -0.0428 0.0613 0.0670 0.0571 0.0686
0.5 0.3 θ̂S -0.0077 -0.0054 -0.0092 -0.0096 0.0464 0.0458 0.0481 0.0504
θ̃S 0.0056 0.0012 -0.0078 -0.0096 0.0508 0.0484 0.0487 0.0504
0.5 θ̂S -0.0095 -0.0024 -0.0199 -0.0333 0.0444 0.0489 0.0507 0.0604
θ̃S 0.0066 0.0062 -0.0194 -0.0333 0.0517 0.0551 0.0511 0.0604
0.7 θ̂S -0.0144 -0.0054 -0.0216 -0.0400 0.0459 0.0506 0.0521 0.0634
θ̃S 0.0063 0.0043 -0.0214 -0.0400 0.0567 0.0616 0.0523 0.0634
0.7 0.3 θ̂S -0.0068 -0.0032 0.0023 0.0137 0.0451 0.0440 0.0448 0.0484
θ̃S 0.0058 0.0018 0.0029 0.0137 0.0500 0.0463 0.0453 0.0484
0.5 θ̂S -0.0072 -0.0035 -0.0001 0.0053 0.0426 0.0427 0.0432 0.0447
θ̃S 0.0084 0.0007 0.0000 0.0053 0.0512 0.0455 0.0433 0.0447
0.7 θ̂S -0.0094 0.0005 -0.0176 -0.0293 0.0412 0.0480 0.0466 0.0535
θ̃S 0.0090 0.0063 -0.0175 -0.0293 0.0525 0.0554 0.0466 0.0535
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Table 7.3: Mean bias and RMSE from 10,000 simulations of the naive estimator (θ̂F ) and the unbiased estimator (θ̃F ) for the
case where F is selected. A range of log HRs θF are considered for subpopulation prevalence pS ∈ {0.4, 0.5, 0.7}, selection times
τS ∈ {0.3, 0.5, 0.7} and selection margin c = 0.
Bias RMSE
θF : 0 -0.22 -0.51 -0.92 0 -0.22 -0.51 -0.92
pS τS Estimator HR: 1 0.8 0.6 0.4 1 0.8 0.6 0.4
0.4 0.3 θ̂F -0.0013 0.1087 0.2508 0.4584 0.0233 0.1110 0.2519 0.4590
θ̃F 0.0017 0.1137 0.2572 0.4650 0.0243 0.1162 0.2584 0.4656
0.5 θ̂F -0.0016 0.1109 0.2524 0.4573 0.0216 0.1134 0.2534 0.4578
θ̃F 0.0019 0.1204 0.2607 0.4644 0.0234 0.1234 0.2619 0.4651
0.7 θ̂F -0.0016 0.1128 0.2542 0.4562 0.0203 0.1152 0.2550 0.4568
θ̃F 0.0024 0.1274 0.2639 0.4633 0.0227 0.1311 0.2650 0.4640
0.5 0.3 θ̂F -0.0002 0.1149 0.2631 0.4771 0.0214 0.1169 0.2640 0.4776
θ̃F -0.0002 0.1184 0.2704 0.4890 0.0214 0.1203 0.2713 0.4895
0.5 θ̂F 0.0001 0.1178 0.2643 0.4771 0.0197 0.1199 0.2651 0.4775
θ̃F 0.0000 0.1254 0.2757 0.4952 0.0201 0.1275 0.2766 0.4957
0.7 θ̂F 0.0003 0.1194 0.2648 0.4758 0.0189 0.1214 0.2656 0.4763
θ̃F 0.0003 0.1321 0.2801 0.4993 0.0198 0.1343 0.2810 0.4998
0.7 0.3 θ̂F 0.0027 0.1001 0.2268 0.4106 0.0277 0.1039 0.2284 0.4115
θ̃F -0.0030 0.0951 0.2231 0.4051 0.0306 0.1000 0.2252 0.4063
0.5 θ̂F 0.0029 0.1016 0.2281 0.4102 0.0250 0.1049 0.2295 0.4110
θ̃F -0.0040 0.0961 0.2231 0.4003 0.0297 0.1009 0.2253 0.4017
0.7 θ̂F 0.0030 0.1079 0.2291 0.4091 0.0240 0.1113 0.2304 0.4098
θ̃F -0.0050 0.0982 0.2227 0.3919 0.0302 0.1068 0.2254 0.3939
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positive subpopulation, then the trial continues to the second stage with the full
population. As the effect sizes are not equal in both subgroups, we cannot directly
estimate the effect in the full population assuming a single parameter model. There-
fore, for the case when F is selected, UMVCUEs were derived for each subgroup
separately and then the treatment effect in the full population was obtained by the
weighted sum of the UMVCUEs for each subpopulation, weighted by the subpopu-
lation prevalences.
Properties of the estimators assessed in a simulation study confirmed the estimators
are only asymptotically unbiased for small effect sizes. Furthermore, for large effect
sizes, simulation results indicated comparable properties of the naive estimator to
the UMVCUE. For the case when S is selected, these results are due to failure of
the normality approximation of the log HR for large effect sizes. For the case when
F is selected, a non-constant hazard ratio in the full population leads to underesti-
mated effect estimates. This is because the proportionality assumption in the full




This thesis focussed on point estimation in two-stage confirmatory clinical trials.
Asymptotically conditionally unbiased estimators for time-to-event data were devel-
oped for two specific settings; the first focussed on treatment selection in seamless
phase II/III clinical trials, and the second focussed on subpopulation selection in
the setting of two-stage targeted therapy trials.
In the former setting of treatment selection, multiplicity issues arise when multiple
treatments are investigated simultaneously. At an interim analysis, based on a pre-
defined selection criterion, the most efficacious treatment is selected to take forward
into the second stage. This selection leads to biased estimation at the final analysis,
as stage 1 data are used for both treatment selection as well as for the confirmatory
analysis, thus resulting in an overly optimistic estimate. There is therefore a need
to correct for this bias in order to obtain an unbiased and thus reliable estimate of
the treatment effect.
For normally distributed outcomes, methods have been proposed that correct for
this selection bias, as presented in Chapter 5. These utilise the technique of Rao-
Blackwellisation, which involves conditioning on the selection rule and complete,
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sufficient statistics to derive a UMVCUE. It was shown that the bias and RMSE
of a naive maximum likelihood estimator (which ignores the selection rule) depend
on several factors including, the effect size, the selection time and the number of
experimental treatments under investigation. When compared by simulation to the
UMVCUE proposed by Kimani et al. [2013], it was found that, although unbiased,
the UMVCUE had a larger RMSE, depending on the selection time. Therefore,
as concluded by several authors in the literature, for normally distributed data, a
trade-off of bias and RMSE should be considered when utilising UMVCUE’s for the
analysis of normally distributed data in seamless phase II/III clinical trials.
Although normalised test statistics may be obtained for time-to-event outcomes, ex-
isting methods of unbiased estimation cannot be applied directly due to the inherent
nature of censoring in time-to-event data. In the setting of seamless phase II/III
clinical trials, censored events at the interim analysis lead to correlated stagewise
data, which were assumed independent in the setting with normally distributed
data. In addition, comparison with a common control arm results in correlated
stage 1 estimates. Chapter 6 therefore addressed these issues by developing new
unbiased estimators that account for both treatment selection bias and correlation
for time-to-event outcomes.
A simulation study investigating the degree of selection bias and RMSE of the naive
estimator, which disregards the selection rule, was presented in Section 6.3. This
study assessed the influence of the effect size and information fraction, as well as the
number treatment arms, and indicated that the naive estimator is positively biased
towards a large effect size. This means that the naive estimator overestimates the
true treatment effect, where it was shown that bias and RMSE increase with the
information fraction (proportion of events observed in stage 1). Furthermore, when
the effect sizes of all treatments are equal, it was concluded that, as the number
of experimental treatment arms increases, bias and RMSE also increase. However,
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when there is a clear superior treatment, bias was found to be roughly constant for
any selection time, which was similarly observed for later selection times in the case
of normally distributed outcomes (see Figure 5.1(c)). Interestingly, however, for the
case of one experimental treatment, where the naive estimator would be expected to
be unbiased, it was found to be slightly negatively biased, that is, it underestimates
the true effect size, possibly due to the correlation from censored observations at the
interim analysis. This simulation study therefore suggested that in addition to the
selection rule, the correlation between stage 1 and 2 data should also be accounted
for in the derivation of unbiased estimators.
To account for this correlation, the concept of independent increments was pre-
sented. This idea, first introduced by Tsiatis [1982], suggests that increment statis-
tics may be defined by the difference between correlated stagewise score statistics,
in order to give an independent covariance structure in the joint distribution of
stagewise statistics. This is most commonly known as the ‘independent increment
structure’ and has allowed group sequential tests in seamless phase II/III clinical
trials to be based on the log-rank test statistic. Therefore, by defining defining
increment log HRs for stage 2, we derived the joint distribution of stage 1 and 2
log HRs with independent stagewise test statistics. This solved the problem of the
correlation between stage 1 and stage 2 data, however the correlation between stage
1 statistics due to the common control arm remains, as in the case with normal
data.
We first considered uncorrelated stage 1 test statistics by assuming a separate con-
trol group for each experimental treatment group, which led to the extension of
the Kimani et al. [2013] estimator. We incorporated the the independent increment
structure and used the method of Rao-Blackwellisation to derive a UMVCUE ac-
counting for selection of the minimum log HR and correlation between stagewise test
statistics. Since the stage 2 increment estimate is unbiased, we sought complete,
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sufficient statistics in order to Rao-Blackwellise the stage 2 increment estimate by
conditioning on the selection rule and the complete, sufficient statistics. This re-
sulted in an estimator of a similar form to the Kimani et al. [2013] and Bowden and
Glimm [2008] estimators, but with the difference of allowing for stage 1 and 2 esti-
mates to be correlated by continuing follow-up of patients censored at the interim
analysis. Therefore, our estimator corrects for both the bias due to selection of the
smallest effect size and the correlation due to censoring. The first component of this
estimator, which includes the increment log HR, is equivalent to the naive estimator
discussed in the motivational simulation study. Hence, this estimator corrects for
the overestimation of the naive estimator.
Since in practice it is common for a trial to include a common control arm, we
extended the previous estimator to correct for the correlation between stage 1 es-
timates, which arises due to the common control arm. Adapting the method by
Robertson et al. [2016], a UMVCUE was derived to correct for selection bias as well
as both the correlation between stage 1 statistics and the correlation between stage
1 and stage 2 data. As before, this estimator also corrects for the overestimation of
the naive estimator but in this case the overcorrection term considers the correlation
between the ordered stage 1 log HRs.
As these estimators were derived based on the assumption of asymptotic normal-
ity of the log-rank test statistic, we may only conclude that these estimators are
asymptotically unbiased. A simulation study was therefore conducted to assess the
performance of these estimators for a realistic sample size with simulated survival
times. A comparison of the naive estimator with the new UMVCUE highlighted
favourable properties of the UMVCUE under certain scenarios. Specifically, due
to normality approximation of the log-rank test statistic, simulation results showed
that this estimator is only asymptotically unbiased for small to moderate effect sizes,
but for any number of experimental treatment arms and selection times.
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Chapter 7 presented the issues in estimation following subpopulation selection in
targeted therapy trials. The need for unbiased and efficient estimators in this setting
led to the development of UMVCUEs for time-to-event data correcting for subgroup
selection and correlation. As in the setting of treatment selection, the problem
of correlated test statistics arises when, at the end of stage 1, patients who do
not experience the event of interest are censored and followed-up further in the
second stage. Therefore, by extension of the methods by Kimani et al. [2015], a
UMVCUE was derived by Rao-Blackwellisation for each possible case of subgroup
selection. If the experimental treatment is not sufficiently more effective in the
biomarker-positive subpopulation, the trial continues to the second stage with the
full population. In this case, UMVCUEs were obtained for each subgroup separately
and the effect in the full population was estimated by the weighted sum of the
UMVCUEs for each subgroup. Properties of the estimators assessed in a simulation
study showed favourable properties of the UMVCUE in the case where S is selected,
for small effect sizes. However, in the case where F is selected, simulation results
indicated comparable properties of the UMVCUE to the naive estimator.
In conclusion, this thesis developed asymptotically uniformly minimum variance
unbiased estimators, conditional on selection rules, for use in the analysis of time-
to-event data. Due to the asymptotic assumptions, these estimators are only appro-
priate for large samples with small to moderate effect sizes. As phase III trials are
confirmatory in nature, such that they are designed with large numbers of events in
order to achieve adequate power to detect large effect sizes, the asymptotic assump-
tions of these estimators would be satisfied under these conditions. These methods
therefore contribute to the statistical methodology for unbiased and efficient esti-
mation of time-to-event outcomes in the setting of two-stage confirmatory clinical
trials with treatment selection or subpopulation selection.
139
8.1 Further work
The following list suggests areas for further work.
(i) In Chapter 7, for the case where the full population is selected to continue in
the second stage, an unbiased estimator was presented based on the weighted
sum of the UMVCUEs for each of the biomarker-positive and biomarker-
negative subpopulations. It would be of interest to directly estimate the
treatment effect from the full population, rather than weighting estimators
by the subpopulation prevalence.
The asymptotic joint distribution under the null of stage 1 and 2 estimates for

































However, this density only holds if the effects in each subpopulation are equal,
that is, if θS = θSc . This is because it is not appropriate to fit a model
with a single parameter when the effects in each subgroup are expected to
be different. Therefore, further work is needed to derive the joint density of
the estimators for the effect in the biomarker-positive subpopulation in stage 1
and the full-population estimate from both stages. It would then be of interest
to compare the results from the weighted estimator given in equation (7.15)
with the estimator obtained from the correct joint density.
(ii) Brückner et al. [2017] recently proposed a shrinkage estimator based on the
asymptotic normality approximation of the log HR obtained from a Cox PH
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model for time-to-event data. Their estimator accounts for treatment selection
in two-stage trials. Brückner et al. compare the naive estimator obtained
at the final analysis with both their shrinkage estimator and the estimator
proposed by Stallard and Todd [2005] for normally distributed data. Their
estimator showed favourable properties when compared to the Stallard and
Todd estimator, in particular for MSE. In a similar way to Brückner et al. it
would worthwhile to develop a shrinkage estimator, but based on the log-rank
test statistic. This estimator can then be compared to the UMVCUE derived
in Section 6.8.
(iii) As the main assumption of the estimators developed in this thesis is that
of asymptotic normality of the log HR, further work to develop estimators
specific to survival distributions would be of value. Shen and Cheng [2006]
provide an estimator for the simple case where one experimental treatment
is compared to a control and the only adaptation at the interim analysis is
that of early stopping for futility or efficacy. This method may be extended to
include a predefined selection rule, either for the case of treatment selection,
where two or more experimental treatments are investigated in the first stage
with the aim of selecting the best performing treatment, or for the setting of
subpopulation selection. A uniformly minimum variance unbiased estimator,
conditional on selection, for specific survival distributions could then be de-
rived. These estimators could then be compared to those developed in this
thesis for time-to-event data.
(iv) Results from simulated data were presented in this thesis in order to compare
the estimators developed under various trial scenarios. It would be of value
to apply these methods to real trial data in order to confirm the applicability
of these estimators for a real trial setting, where problems may arise such as
failure of the proportional hazards assumption.
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(v) In general, novel statistical methods are not frequently used in practice due
to the lack of readily available software. Therefore, it would be beneficial to
develop an R package to aid implementation of these estimators. An example
of this is the ‘asd’ package [Parsons, 2016], which provides functions for hy-




Proof of expectation of a
truncated normal
Let X have a normal distribution with mean µ and variance σ2, then the expectation












































































































(x2 − 2µx+ µ2) + tx
= − 1
2σ2
(x2 − 2x(µ+ σ2t) + µ2)
= − 1
2σ2
(x2 − 2x(µ+ σ2t) + (µ+ σ2t)2 − (µ+ σ2t)2 + µ2)
= − 1
2σ2
(x2 − 2x(µ+ σ2t) + (µ+ σ2t)2) + 1
2σ2
(µ2 + 2µσ2t+ σ4t2 − µ2)
= − 1
2σ2























































































Proof of sufficiency and
completeness of θ̃∗
This proof follows from Robertson et al. [2016]. For simplicity, the notation from
Section 6.8 is changed as follows.
Let the vector of stage 1 log HR’s, θ̂, be denoted byX = (X1, ..., XK) with unknown
true log HRs µ = (µ1, ..., µK) and covariance V = Vij for i, j ∈ {1, ...,K}. Let
Y denote the stage 2 increment statistic θ̃21 for the selected treatment such that
Y ∼ N(µ, τ2). Finally, let Z = (Z1, ..., ZK) denote the sufficient and complete
statistics θ̃∗, which we want to show are sufficient and complete for θ.
Proof.
Recall the selection rule Qs defined in Section 6.2. Following Equation (6.20) the
joint distribution of (X, Y ) given Qs has the density
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(B.2)






























µi − µ′Pµ− 1
τ2
µ21 + ψ (x, y)

(B.3)
where ψ (x, y) = −x′Px− 1
τ2
y2.

























µi + µ′Pµ− 1
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pijxj for i = 1, 2, . . . ,K.
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By Definition 3.4.8, it can be concluded that T is also a complete statistic since
density (B.4) is in natural parametrisation of an exponential family (3.7) and the
natural parameter space contains a K−dimensional rectangle.
Now, in order to get the required sufficient statistic, linear combinations of T are
formed. First consider if V1i 6= 0 for i = 1, 2, . . . ,K.
Let














































































=⇒ Zi = xi +
V1i
τ2
Y is sufficient for µi.
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Hence, Zi = Xi +
V1i
τ2
Y is sufficient for µi. Therefore, since Z is a linear transfor-
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Lehmann, E. L. and Scheffé, H. (1950). Completeness, similar regions, and unbi-
ased estimation: Part i. Sankhya: The Indian Journal of Statistics (1933-1960),
10(4):305–340.
Lindgren, B. (1993). Statistical Theory, Fourth Edition. Chapman & Hall/CRC
Texts in Statistical Science. Taylor & Francis.
Machin, D., Campbell, M. J., Tan, S. B., and Tan, S. H. (2009). Sample Size Tables
for Clinical Tials. John Wiley & Sons Ltd, Chichester, third edition.
Machin, D., Cheung, Y. B., and Parmar, M. K. (2006). Survival Analysis: A
Practical Approach. John Wiley & Sons Ltd, Chichester, second edition.
Machin, D., Day, S., and Green, S. (2004). Textbook of clinical trials. John Wiley
& Sons Ltd, Chichester.
Mehta, C., Schäfer, H., Daniel, H., and Irle, S. (2014). Biomarker-driven population
enrichment for adaptive oncology trials with time to event endpoints. Statistics
in Medicine, 33:4515–4531.
Ondra, T., Dmitrienko, A., Friede, T., Graf, A., Miller, F., Stallard, N., and Posch,
M. (2016). Methods for identification and confirmation of targeted subgroups
in clinical trials: A systematic review. Journal of Biopharmaceutical Statistics,
26(1):99 – 119.
O’Quigley, J., Pepe, M., and Fisher, L. (1990). Continual reassessment method: A
practical design for phase 1 clinical trials in cancer. Biometrics, 46:33–48.
Parsons, N. (2016). asd: Simulations for Adaptive Seamless Designs. R package
version 2.2.
Peto, R. and Peto, J. (1972). Asymptotically efficient rank invariant test procedures.
Journal of the Royal Statistical Society, Series A, 135:185–207.
153
Piantadosi, S. (2005). Clinical Trials: A Methodological Perspective. John Wiley &
Sons Ltd, New Jersey, 2 edition.
Posch, M., Koenig, F., Branson, M., Brannath, W., Dunger-Baldauf, C., and Bauer,
P. (2005). Testing and estimation in flexible group sequential designs with adap-
tive treatment selection. Statistics in Medicine, 24:3697–3714.
R Core Team (2017). R: A Language and Environment for Statistical Computing.
R Foundation for Statistical Computing, Vienna, Austria.
Robertson, D. S., Prevost, A. T., and Bowden, J. (2016). Accounting for selec-
tion and correlation in the analysis of two-stage genome-wide association studies.
Biostatistics, 17(4):634–649.
Roussas, G. (2007). Introduction to Probability. Elsevier Academic Press.
Royston, P. and Lambert, P. C. (2011). Flexible Parametric Survival Analysis Using
Stata: Beyond the Cox Model. StataCorp LP.
Rubinstein, L. V., Korn, E. L., Freidlin, B., Hunsberger, S., Ivy, S. P., and Smith,
M. A. (2005). Design issues of randomized phase II trials and a proposal for phase
ii screening trials. Journal of Clinical Oncology, 23:7199–7206.
Sargent, D. J. and Goldberg, R. M. (2001). A flexible design for multiple armed
screening trials. Statistics in Medicine, 20:1051–1060.
Schäfer, H. and Müller, H.-H. (2001). Modification of the sample size and the
schedule of interim analyses in survival trials based on data inspections. Statistics
in Medicine, 20(24):3741–3751.
Sheiner, L. B. (1997). Learning versus confirming in clinical drug development.
Clinical Pharmacology & Therapeutics, 61(3):275–291.
Shen, L. (2001). Estimation following selection of the largest of two normal means.
Statistics in Medicine, 20:1913 – 1929.
Shen, Y. and Cheng, Y. (2006). Adaptive design: estimation and inference with
censored data in a semiparametric model. Biostatistics, 8:306 – 322.
Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled
Clinical Trials, 10:1–10.
Simon, R., Wittes, R. E., and Ellenberg, S. S. (1985). Randomised phase II clinical
trials. Cancer treatment reports, 69:1375–1381.
154
Stallard, N. and Todd, S. (2003). Sequential designs for phase III clinical trials
incorporating treatment selection. Statistics in Medicine, 22:689–703.
Stallard, N. and Todd, S. (2005). Point estimates and confidence regions for se-
quential trials involving selection. Journal of Statistical Planning and Inference,
135:402 – 419.
Stasinopoulos, M., Rigby, B., Akantziliotou, C., and Ospina, R. (2006). gamlss.dist:
Distributions for Generalized Additive Models for Location Scale and Shape. R
package version 1.5.0.
Tarone, R. E. and Ware, J. (1977). On distribution-free tests for equality of survival
distributions. Biometrika, 64(1):156–160.
Tsiatis, A. A. (1982). Repeated significance testing for a general class of statistics
used in censored survival analysis. Journal of the American Statistical Association,
77(380):855–861.
Wassmer, G. (2006). Planning and analyzing adaptive group sequential survival
trials. Biometrical Journal, 48(4):714–729.
Wassmer, G. and Brannath, W. (2016). Group Sequential and Confirmatory Adap-
tive Designs in Clinical Trials. Springer Series in Pharmaceutical Statistics.
Springer International Publishing.
Whitehead, J. (1997). The Design and Analysis of Sequential Clinical Trials. John
Wiley & Sons Ltd, England, 2 edition.
Xi, D., Glimm, E., and Bretz, F. (2016). Multiplicity, chapter 3, pages 69–104. In
George et al. [2016].
Young, G. A. and Smith, R. L. (2005). Essentials of Statistical Inference. Cambridge
Series in Statistical and Probabilistic Mathematics. Cambridge University Press.
155
